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3-Deazapyrimidine nuc1eosides have been shown to exhibit great potential as 
pro drug for use in meclicine especially as antagonists to cancer tumors and the fUV­
virus. Recent research has focused on the design, synthesis and characterization of 
novel nucleoside analogues. 
Fluoropyridinone and their corresponding nucleoside derivatives have been 
synthesized and characterized to induce the activity against tumors. 4,6-diaryl-3-
cyano-2(J H)-pyridinones (82 a-i) and their nucleosides were prepared. A 
tIifluoromethyl group was introduced into the pyridinone ring system to study its 
effect on different tumor cells. The glycoside analogues (83a-e, 8Sa-e, 87a-e and 
88a-d) have been synthesized in good yield via the reaction between pyridinone 
derivatives and an activated hexapyranosyl sugar to give N-nuc1eosides (83a-e, 8Sa-e, 
87a-e and 88a-d) as the sole product. In our biological screening, it was found that 
the fluorine and trifluoromethyl derivatives of the pyridine ring enhance the biological 
activity Moreover, the novel non-nucleoside derivatives (89a-d) are found to be more 
active than the corresponding N-nuc1eosides. This enhancement in biological 
properties is due to the presence of the fluorine groups on the pyridine ring. 
Computer aided Quantum Mechanics (QM) calculations using density 
functional theory (DFT) were used to study the reactivity of 3-deazapyrirnidines with 
activated sugar molecules. Gaussian 98 was employed for the calculation of 
geometries and energies. Charge density gas phase calculations were performed at 
the B3L yP level with the 6-31 G basis set. The data obtained from QM calculations 
supports our experimental results by showing higher charge density on the pyridine N­
atom than on the oxygen atom at C-2. HOMO-LUMO charge density studies of the 
isolated compounds are fully consistent with the spectroscopic results. 
VIi 
tructure- ctivity Relationships (SAR) of nuc1eosides (83a-e, 8Sa-e, 87a-e 
and 88a-d ) and other non-nucleosides (89a-d) showed an interesting biological 
activity. tructure-activity relationships studies of 3-deazapyrirnidine derivatives were 
used to determine the parts of the structure that are responsible for its biological 
activity and its side effects according to the nature of the substituents. The results 
ha e shown that 2-thiophene at the 4-position has the highest activity among all 
analogues. In addition, the aryl group at the 6-position has shown similar activities. 
For e ample, 4-(thiophen-2-yl)-6-phenyI-3-cyano-2(1H)-pyridinones (82d) and 4-
(thiophen-2-yl)-6-(p-chlorophenyI)-3-cyano-2( IH)-pyridinones (82e) have shown the 
same activity at lower and higher concentrations. This result indicates that aryl 
groups at the 6-position have the same effects, based on the results obtained from 
biological screening. Meanwhile, nucleosides containing the glucopyranosyl ring 
system showed higher activity than the galactose isomer. For example, compounds 
(83a-e) have shown better activity than the corresponding galactoside analogues (87a­
e). All free nucleosides showed higher activity due to the solubility factor, where the 
low soluble acetylated derivatives showed good activities. 
2-Thiophene present at the 4-position showed promising biological activity in 
both nucleosides and non-nuc!eosides. Meanwhile, more interesting results were 
obtained from the non-nucleoside analogues (89a-d). SAR has explained these results 
as follows: 
The solubility facter might not be the dominant factor because even the low soluble 
non-nucleoside (89a) was found to have the highest potential activity. 
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1 .  Introd uction 
The \J ord "nucleoside" OliginaUy coined by Levene and Jacobs at 1909(1) for some 
time refen"ed to compounds isolated from nucleic acids, contained a carbohydrate attached 
through a nitrogen to either a purine or pyrimidine base. Currently, a nuc leoside is defined as 
a compound of  natural or synthetic origin that has a carbohydrate attached to a nitrogen 
heterocycle  through either a carbon-nitrogen bond,  as is commonly found, or a carbon-carbon 
bond as found in C-nuc1eosides. 
There are two major bases found in natural nucleosides. Purines (Adenine A, and 
Guanine G) consist of  a s ix-membered and a five-membered nitrogen-containing ring, fused 
together and Pyrimidines (Cytosine C, Thymine T and Uraci l  U) which have only a six-
membered nitrogen-containing ring (Figure 1). 
N�2 
< --l.J N N H 
Adenine A Guanine G 
Purines 
0 cr:� I NAo '{NH NAo H H 
Cytosine C ThymineT 
Pyrimidines 
0 CNH NAo H 
Uracil U 
Figure 1 :  Structures ofnucleic acid bases 
The bases may be attached to different sugar residues such as hexapyranoside. The 
glycosidic bond is fOITIled between the anomeric carbon atom of the carbohydrate moiety (C-l 
1 
of the sugar) and a ring of the heterocyclic base. The bases are attached to C-l of the sugar 
unit, through N-9 of a purine or N-J of a pyrimidine (Figure 2). 
¢� (1: HO� HO� 
OH OH OH 
Cytdlfle Deoxyadenosine 
Figure 2: Structures o f  p-form of Cytidine and Deoxadenosine 
The nucleosides may have two different configurations, the 0.- or fJ- configuration. In 
the a- fon , the glycosidic bond and 2-0H adopt an axial-equatorial con-elation, while in the 
fJ-forrn the glycosidic bond and 2-0H are in the equatorial-equatorial relationship (Figure 3). 
fJ-isomer a-Isomer 
Figure 3: Structures o fan /3-and a-isomers o f Deoxycytosine 
In the first approximation, the plane of the heterocyclic base in a nucleoside is almost 
perpendicular to the "folded" plane of the sugar. The sugar moiety itself in a nucleoside 
usually exists in one major thennodynamically stable confonnation. The 4C1 is 
thennodynamically a more stable isomer than the lC4 conformations of the hexapyranosides 
2 
sugar (Figure 4). Similarly, the pentapyranoside and pentafuranoside ring structures exist in 
one preferred confonnation. 
1 . 1  S,'nthesis of N ucleosides 
The chemistry o f  nuc1eosides is rapidly becoming a very attractive area of research. 
This is due to the fact that the study of structures and biological applications require a large 
number o f  new syntheti c  nuc1eosides. It is reasonably expected that the nucleoside analogues 
will exhibit d ifferent activities through the interaction at many enzymatic pathways of  
synthesis and metabolism ofnucleosides, nucleotides, DNA and RNA respectively. 
There are two main approaches to the synthesis of  pyrimidine nuc1eosides. The first 
one is based on the reaction between an activated pyridinone substrate or i ts derivatives and 
I-halo-or I-acetoxy-substituted sugar derivatives in which the hydroxyl groups are protected 
with acetyl or benzoyl groups. A less common approach involves construction of a pyridine 
. (23) nng system . .  
3 
1 . 1 .2 Co nden ation Method Us ing Protected Sugar Derivatives 
The following e amp\es illustrate the application of this method: 
1 . 1 .2. 1 Metal alts Method 
The first synthesis of  nucleosides was accomplished by Ficher and Helferich(4) in 
1 9 1 4  by the reaction 0 f silver derivatives of naturally occuning pyrimidine with g\ycosy\ 
halides. It \\ as shown that the monomercuri derivatives of N' -acetylcytosine (1 ) condensed 
with 2,3 4-tri-O-acetyl-D-ribo furanosyl chloride (2) gave the cytosine nucleoside (3). In a 
similar way, the treatment of  the mercury salt of  thymine (4) with (2) afforded a thymine 
nucleoside (5) (Equations 1 and 2). 
NH2 
NHAc � 
�N 1- HgC12 • eX 
o l--O�Cl 0 l .. � BzO BZ0-qN 0 H 2- )--( 
OBz OBz OBz OBz 








1: 1- HgC12 





On the other hand, treatment o f  the silver sal t  o f  uraci l  (6) with tetra-O-acetyl-a-D-
glucopyranosyl bromide (7 )  gave a mixture o f nucleosides 1 -(2 ' ,3',4 ' ,6'-tetra-O-acetyl-J3-D-
glucopyranosyl) uraci l  (8)  and 2,4-b is (2 ' ,3 ',4 ' ,6'-tetra-O- acetyl-�-D-glucapyranosyloxy) 












0 I I . 
AcO y
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Ac; 1 OAc � 




Scheme 1: Synthesis o fmono- and bis N-glucoside using silver salt 
When the reaction \ as repeated with the silver salt of thymine (1) under similar 
conditions the products were N1_ glucoside (10) 2,4-bis-O-glucoside (11) and N\N3 -isomer 
( 1 2) (Scheme 2). 
(1) 





OAe (7) Br 
�OAe 0 O --,.("�N� 





OAe �- _D 
�(' T AeO N NH AeO y 
OAe 
OAe II o 
10) 
AeO�N:XCH) 
AcO OAc + 




Scheme 2: Formation o fmono- and b is N-glucoside as well as the bis O-glucosides 
5 
A successful attempt to synthesize purine nucleosides was reported by Davoll and 
Lo\\ry.(6) They obtained pUline nucleosides by condensation of  the mercury delivative of 6-
benzoyJpUline (13) with 2 3 ,5 -tri-O-benzoyl-D-ribofuranosyl bromide ( 1 4). The product of 
th is reaction was a mixture of (X- and ,B-nucleosides (1 5)  and ( 1 6) respectively CEq uation 3). 
BZO, ............. O ............. . 
+ �Br 
OBz OBz 




BzO N-lN) ~ 
OBz OBz 
(15) 








In 1 930  Hilbert and Johnson developed the [liSt general method for the synthesis of  
nucleosides.(7) 2,4 -Dialkoxy pyrimidine (17)  reacted with 2,3,5-tri-O-acetyl-D-libofuranosyl 
bromide ( 1 8) to produce via ammonolysis the non isolated intermediate ( 1 9) cytidine(8) (20). 
The advantage o f  this method is that the intermediate ( 1 9) contains a reactive group at C-4 
which can be easily displaced by a nucleophile as in the synthesis of (20), or can be 
















(18) l U1C 
O-SoC 
OR (:N NH] I 
N�OR CHJOH eN I NAO 
A
�� HO� OAe OAe OH Oll 
(19) (20) 
cheme 3: Synthesis of cytosine and uracil from the same intennediate 
'vVhen 2 4-diethoxypyrimidine (22) was treated with 2 ,3 ,5 -tri -O-benzoyl 
-D-ribofuranosylchl oride (2) in acetonitri le  at 0-5 °C followed by alcoholic ammonia, 2 ,4-
diamino- l -(B-D-ribofuranosyl) pyrimidinum chloride (23) was 0 btained(9) (Equation 4). 
1- (2) CH)CN (O-S°C) . (4) 
(22) 
1.1.2.3 Fusion Method 
On the major advances in  nucleoside synthesis was the introduction of the fusion 
method by Shimadate and co-workers(lO-12) In its original form the method consisted of 
heating the aglycon under vacuum with polyacetylated sugar in  an acidic medium. Sato and 
co-workers (13) used this method to prepare 2-methylthioadenine n ucleosides .  Two isomeric 
nucleosides (26) and (27) were obtained by the fusion o f 2 ,6-dichloropurine (24) with sugar 
7 
derivatives (25) in the presence of  a catalytic amount of  chloroacetic or dichloroacetic acid 
followed by the treatment with ammonia (Scheme 4) .  CI 
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Scheme 4: One-step synthesis of a- and ,B-isomers o f deoxyadenosine derivatives 
A long number o f  catalysts have been successfully employed for the fusion reaction 
including zinc chloride, aluminum chloride, sulfur trioxide, sul famic acid , iodine and 
polyphosphoric acid. ( 14.-17) 
By contrast, a similar reaction of  2 ,6-dibromopUline (28) with 1 ,2 ,3 ,5 -tetra-O-
acetylribofuranose (29) at 1 60- 1 7 0  °C produced a protected n ucleoside (30) in a good yield. 
The corresponding n ucleoside (3 1 )  was obtained by treatment of (30) with ammonia(13, 18) 





cfA + �OA' 
II Br OAc OAc 
(21!) (29) 
1- fusion 
160-170oC' elL A'0'8 B, 
OAc OAc (30) 
S ell erne 5: Synthesis of subsitituted adenosine via fusion 
1 . 1 .2.4 The Si ly l  Method 
Use of trimethylsilyl derivatives of  heterocyclic bases as reagents in nucleoside 
synthesis was reported by BrikhoferC19) and by Nishimura and co-workers (20) The synthesis 
of nucleosides involves two steps: the first is the formation o f  the silyl intermediate while 
the second is the condensation between the resultant silyl derivatives with an activated sugar. 
The major silylating agents are: chlorotrimethylsilane Me3SiCI, (TMSCI), hexamethyl 
disila.zane Me3SiNHSiMe3 (HM DS), silylated acylamides such as Me(OSiMe3)C=NSiMe3 
and aminotriethyl silane EbSiNH2. In the preparation of uri dine (2 1 ), uracil (6) was treated 
with excess of  HM DS and TMSCl; then the silyl intermediate (32) was allowed to react, 
without isolation ,  \ ith 2 3 ,5-tri-0-benzoyl-D-ribofuranosyl chloride (2) followed by 
hydrolysis with base to produce the same product (2 1 ) (Scheme 6). An especially useful 
modification o f  the trimethylsilyl method is the use of silylated pyrimidines (32) with 1 -0-
9 
acetyl-2 3 ,5 -tri-O-benzoyl -J3-D-ribofuranose (33)  in the presence o f a  Fliedel-Crafts catalyst, 



















Scheme 6: Synthesis ofuracil by two di fferent methods 
In general , the silyl method is particularly useful for the synthesis of pyrimidine 
nucleosides, which can be used to complement the fusion synthesis which is generally more 
suitable for preparing purine  nucleosides. The use of  mercuric salts in the reaction holds a 
great potential to extend the method to purine nucleosides. Two isomeric nucleosides (37) 
and (38) were obtained by the reaction between the bistrimethylsilyl purine derivative (36)  
and 2 ,3 ,5 -tri-O-bezoyl-D-ribofuranaosyl bromide (14) in benzene at room temperature in the 
presence of mercuric bromide (Scheme 7). 
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Scheme 7: Synthesis o f  N7 and t.f nucleosides using HgBr2 
1 . 1 .3 Co nstruction of the Pyrimidine and Purine R ing System 
The methods discussed above involve a reaction between a h eterocycl ic base and a 
sugar. This general metho d  has been used to prepare both purine and pyrimidine nucleosides. 
1 . 1 .3 . 1 Construction of Pvrim idine Ring System 
The first pyrimidine n ucleoside synthesis using ring closure was reported in 1 95 8  by 
Show (:!l, 22) Uridine (2 1 )  was obtained by the reaction between the ribosylamine derivative 
(39) and ,8-ethoxy-N-ethoxycarbonylacrylamide fol lowed by hydro lysis. A thio nucleoside 
derivatiye (40) was obtained by using a.-methoxy-,8-methoxyacryloyl isothiocyanate.(20) ,8-
isomer was isolated in both cases even though the anomeric mixture o f  (39) was used 
(Scheme 8 ). 
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S cheme 8: Synthesis ofpyrimidine nucleosides using ring closure 
1.1.3.2 Construction of the Purine Ring System 
A number of purin e  n ucleosides have been prepared by the construction of the 
heterocycl ic  system after the C-N glycosidic linkage had been fonned. The irnidazol 
n ucleoside (41) is a pivotal intermediate in the synthesis of the pUline nucleoside by ring 
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S ell em e 9: Synthesis of purine nucleosides using ring construction 
1.1.4 Effects of Catalyst and Solvent  
Pyrimidine and purine nucleosides can be synthesized by the reaction of silyl 
heterocyclic bases with peracetylated sugars in the presence of Friedel-Crafts catalysts.(23) 
However, these procedures s ti l l  demand the prior silylation o f  the heterocyclic bases to the 
highly moisture-sensitive silyl derivatives. F urthermore the perfluoroalkane sulfonic and 
perchloric acids or their corresponding salts have to be converted to trimethylsilyl triflateY4) 
It is also found that, Lewis acid catalysts such as (CH3)3SiS03CF 3 or SnCl4 and the 
peracylated sugars derivatives can be combined to effect nucleoside formation in one simple 
synthetic step in high yield (85%/25). Under this one step condition, the solvation affects the 
reactivity of the n ucleophilic centers even stronger than any o ther factors. Since Friedel-
Crafts catalysts such as SnCk or TiC14 had been used successful ly for the Silyl-Hilbert-
Johnson nucleoside synthesis(25) these new silylated Lewis acids TMSC I 04 and TMSOTf 
were reacted with silylated uracil (28) and (33). It was found that catalytic amounts of 
TMSC 1 04 or TMSOT f in 1,2-dichloroethane or acetonitrile were adequate for generating the 
1 3  
reactive intelmediate cation (44), although the use of 1 . 1  equi alents was more efficient. 
Reaction of (44) \: ith silylated uracil (28) lead to the silylated intermediate (45) and 
regenerated TMSC 1 04 or TMSOT[(26,27) Hydrolysis of  (45) in aqueous NaHC03 produced 
2' 3 ' ,5 ' -tri- O-benzoyluridine (34) in more than 80% yield (Scheme 1 0). 
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Scheme 1 0 :  Schematic mechanism o f tribenzoyluracil formation 
In contrast to TMSCl04 and TMSOTf, the weaker Lewis acids (28) (TMShS04 and 
TMSCI do not promote nucleoside formation, since they do not convert (33 )  into the sugar 
cation (44). H owever the even weaker Lewis acid TM SI which can be prepared in situ from 
TMSC I and NaI in acetonitrile, does catalyze the formation o f  nuc1eosides (29,30) The use of  
TMSOTf as a catalyst dramatical ly increases the yields of  the 5 -methoxy- or  5-morpholino-
2 ' ,3 ' ,5 ' -uridine tri-O-benzoates (47b) and (48c)  from the silylated uracils (46b,c) and (33 ). This 
is even significant  in 1,2-dichloroethane; 89% of (47b) (compared to 53% using SnC 1 4) and 95% 
of  (47c)  (compared to 3 9% using SnC 1 4) are obtained. Analogously, use of  catalytic TMSOTf 
with the rather basic silylated 4-trimethylsilyloxypyridine (50a) and 4-
trimethylsilylaminopyridine (SOb) gave the corresponding nucleosides (51a) and (S I b) in 87% 
1 4  
and 80% yields,(27) whereas (5 1 a) is obtained only in 63 % yield with SnC l }3I) (Equations 7 and 
8 ) 
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Under carefully controlled conditions usmg TMSOTf in purified acetonitri le, 
s i lylated 6-methylurac i l  (52) produced the desired protected 6-methyluridine (53) in 7 1  % 
yield compared to 4 1  % with SnC 1 4 (Scheme 1 1 ). 
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Scheme 1 1: S ynthesis o f 6-methylpyrimidine-2,4-dione nucleosides 
Furthermore the undesired J'.f -nucleoside (54) rearranges by heating with TMSOT f 
to give a 5 3 %  yield of  the protected N1-nucleoside (56) and a 3 3 %  yield o f  the N\ N3_ 
bis(riboside) (55). The sterically h indered (55) reacts on heating with si lylated 6-
methylurac il (52) and TMSOTf to give the conesponding Nt-nucleoside (53l27) (Scheme 
1 2) .  
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Scheme 1 2 :  Synthesis of 6-methylpyrimidine-2,4-dione nucleosides 
1 . 1.5 TransglYcosv lation 
Transglycosylation was first investigated by Licbtentbaler and co-workers(32) by treating 
peracylated cytidine (57) with N'-benzoyladenine (35)  in the presence o f HgBr2 and DMA in 
xylene to afford after saponification (58) and it's a-isomer (59P2) (Scheme 1 3) .  
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Scheme 1 3 :  Pyrimidine-purine transglycosylation 
Heating o f  (60) in toluene in the presence of HgBr2 resulted in an 0-4N transglycosidation to 
giye a mixture of a- and /3- isomers(JJ) (61) and (62) (Scheme 1 4) .  
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S ch eme 1 4 :  Synthesis ofan a- and [3- isomers (O-N transglycosidation) 
1 8  
1 . 1 .6 :::..J...;==.::......:::..=-=-=:..:::..:..:===== 
There are several methods to synthesize deazanucleoside. The basic 4-pyridone (63 )  
reacts via a silyl intermediate \ ith 1 -0-acetyl-2 3 ,5 -tIi-O-benzoyl -D-ribofuranose (33), 
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The b is(trimethyls i lyl) derivative of  2 ,4-dihydroxypyridine (65)  is condensed with 
2 ,3 ,5-tIi-O-acetyl-D-ribofuranosyl bromide (1 8)  to afford a protected nucleoside (66) in a 
78% yield The corresponding free nucleoside (67)  is obtained by treatment of (66) with 
ammonia(34) (Scheme 1 5) .  
1 9  




S ch eme 1 5: Synthesis of 4-hydroxy-2-pyrid inone nucleoside 
Niedballa  and Vorbruggen (3 1) reported that the reaction o f  2-trimethyl s i lyloxy 
pyridine (68) with 1 -0- acetyl-2,3 ,5 -tri-0-benzoyl-,B-D-ribofuranose (33) in the presence of 
SnC14 gave the corresponding pyridinone nucleoside (69). Subsequent treatment of (69) with 
methanol ic ammonia yielded the free nucleoside (70) (Scheme 1 6) .  
(68) 
(33) 




Scheme 1 6 : Synthesis of2-pyridinone nucleoside 
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The preparation of 4-amino-3 -fluoro- l -(2 ' 3 ' ,5 ' -tri-O-bezoyl-,B-D-ribofuranosyl)-2-
pyridinone (72)  by the reaction of the bis(trisi lylmethyl) derivative of 4-amino-3-
O uoropYIidine (7 1 )  with a ribose derivative (33) has been reported(35) (Equation 1 0) 
(33) 
I H 
(7 1 ) 
�, 
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BzO/ 
H BzO OBz 
(72) 
( 1 0) 
5 - Fluoro-3-deazaulidine(36) (74) was obtained by the reaction between the 
trimethyls i lyl deri,'ative o f  (73) and a ribose derivative ( 18), fol lowed by the treatment with 
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A comparative s tudy that involved two s ilyl pyridines (75a,b) differing in the C-2 
substituent and a bulky sugar derivative (76) has attracted a lot of  interest (Equation 1 2). The 
reaction of 2 -pyridinone (74) gave the pyridinone nucleoside (78). Similary, the 2-thiono 
isomer (75) resulted in the formation of the thionopyridine nucleoside (79). 
2 1  
( Sa) .x c- II) X S (78) X 0 (79) X S 
( 1 2) 
In addition , it was found that for preparation of  deazap)'limidine nucleosides reported 
by Elqemeie and co-workers (37,3 ) 3 -deazapyrimidine glycosides (8 1 )  were obtained by the 
reaction of the K-salt o f  ( 0) with an acti ated sugar derivative (7)  in 70-85% yield 
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AIMS A..�D OBJECTIVES 
1.2 �=:....::a:..:n�d�O�b�i..:::e.:::.ct�i..:...ve= 
The aims of the pre ent study are . 
1 . To synthesize some no\'el 3-deazapyrimidines and their nucleosides using an easy 
dIrect method 
2 To te t the pUJi ty and to tudy the mechanisms of the obtained products 
To con fi IID the obtained structures using di fferent techniques such as FT - IR 
spectro copy 1 D- and 2D-NMR, 13C-NMR elemental analysis as wel l as quantium 
mechan ics calculations . .  
4 . To study the biological activity of  the obtained products. 
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MATERIALS AND METHODS 
enera l :  All air sensitive materials were handled under a nitrogen atmosphere. Mp 's 
Pyrex capi l l:uy) are not corrected ln lhred spectra \ ere recorded with a Thermo icolet 
exus 470 FT - I R  spectrometer in the range 4000-400 cm-l on samples in potassium bromide 
disks l H_ M R  spe tra 200 M Hz) and 13C-NM R spectra (75 .0 M Hz) were obtained on a 
arian 2 00 1 Hz instlUment; chemical shifts \: ere recorded in 8 (ppm) units, relative to 
1e-l i as an internal standard at 0.0 ppm. The spin multipl icities are indicated by the 
symbols s (singlet) d (doublet), t (triplet) m (multiplet) and b (broad). Optical rotations 
were measured with a Perkin-Elmer digital polarimeter at 5 8 9  nm (sodium D line) in a I dm 
cell Thin-layer chromatography (TLC) was carried out on precoated M erck si l ica gel F25-1 
plates and UV light was used for visualization. Column chromatography was performed on 
a M erck si l ica gel .  Microanalytical data (C, H N S) were performed on a Flash-EA- l l 1 2 
series analyzer and were within ± 0.5 % for (C, H ,  N) and ± 0. 8 % for S of  the theoretical 
values All other reagents were purchased from Aldrich and used without further 
purification 
2.1 General Procedure for the Synthesis of2(1H)-Pvridinones 
4 6-Disllbistituted-3-cyalto-2(1 H)-pyridinones (82a-i) :  A mixture of an aromatic aldehyde 
( 1 0  mmol),  ethyl cyanoacetate ( 1 0  mmol), or 2-cyanoacetamide, (0.0 1 mol,  acetophenone 
derivatives ( 1 0  mmol) and ammonium acetate (0 . 1  mol) in ethanol (5 0 m L) \: as heated under 
reflux for 6 h. The mixture was cooled, and the resultan t  precipitate was filtered ofT and 
washed with cold H20 (3 x 50 m L) to give a sol id mass. The solid was crystall ized from 
appropriate solvent (ethanol  or DMSO) and dried to give the desired 2 -pyridinone (82a-i). 
24 
4,6-Dipltellyl-3-cyallo-2(1 H)-pyridillolles (82a):  Pale yel low crystals ;  yield 85°'0 from OM 0 
mp 3 3  , Rc - 0 533  (6 4 he ane / ethylacetate), IR (KBr, cm' l) 1 600 (CO), 2220 (C , 3 440 
H), l H _ f R  [OM 0-d6, 200 M Hz] (0, ppm) 6 82 (s, 1 H,  H-5),  7 54-7 89 m, 1 0H, 
aromatic),  1 2  I (bs,  1 H,  H); 1 J  - l R  [OMSO-d6, 200 M Hz] (0,  ppm) 1 06 3  (C-5 ), 
1 1 6 5 (C ), 1 1 6 0  C-3 , 1 27  - 1 3 6 .0 (Aromatic carbons), 1 5 1 . 5 (C-6), 1 59 . 8  (CO ofpyridine), 
1 62 0 ( -4 Anal Calcd for C l H l2 20 (272. 30) C 79. 39 ;  H, 4 44 ,  N, 1 0.29 %, found C 
79 0, H ,  4 46 ,  , 1 0 20 °'0 
4-(o- Tolyl)-6-pltellyl-3-cyano-2( 1 H)-pyridiflolles (82b) :  Pale  yellow crystals ;  yield 67% from 
OM 0 mp 2 4°C, Rc = 0 .3  (6 "4 he ane / ethylacetate), IR  (KBr, cm'l) 1 64 1  (CO), 2350 
(C ) 3420 H);  I H -NM R [DM SO-d6, 200 M Hz) : (8, ppm) 2 .36 (s , 3 H, CH3), 6.7 1  ( s ,  I H, 
H-5 ), 7 . 3 1 -7 89  (m, 1 2H aromatic) 1 2 . 8 1 (bs I H  NH);13C-NMR [DMSO-d6, 200 M Hz] .  (0, 
ppm) 1 07 5 (C-5 ), 1 1 6. 6  (C ) 1 1 6. 0  (C-3)  1 26.7- 1 3 7 . 1 (aromatic carbons), 1 5 1 . 9 (C-6), 1 6 1 . 8 
(C-2), 1 62 4 C-4 Anal . Calcd for Cl9HI4N20 (286. 33 ): C, 79 .70,  H ,  4 .93 ;  N, 9 .78 ;  found '  C, 
79.90; H, 5 06, , 9 . 87% 
4-(m- Tolyl)-6-phellyl-3-eyaflo-2(1H)-pyridiflofles (82e) : Yellow clystals ; yield 76% from 
D ISO, mp 263 °C, Rc = 0 .26 ( 6 4  hexane / ethylacetate) IR. (KBr, cm'l ) 1 650 (CO), 2229 
(C ) , 3 442 ( H), 
I H-N1vf R [D fSO-d6, 200 M Hz).  (8 ppm) 2 . 36  (s , 3 H, CH3), 6 .77 (s I H), 
7 34-7 89  (m, 1 2 H, aromatic), 1 2 . 8 1 (bs ,  I H, NH); I3C-NMR [DM SO-d6, 200 M Hz) : (8, ppm) 
98 4(C-3)  1 06 3  (C-5), 1 1 6 6  (CN) 1 25 .4- 1 3 8 . 3  (aromatic carbons), 1 5 1 .4 (C-6), 1 59.9 (C-2), 
1 62 .2 (C-4) ,  Anal. Calcd for CI9 H I4N20 (286.33 ) :  C, 79.70; H, 4 . 93 ;  N, 9 .78  %, found'C, 
79.70, H 5 04 N, 9 .77 % 
4-(Thiophefl-2-yl}-6-p henyl-3-eyallo-2(1H)-pyridillofles (82d) :  Yellow crystals; yield 73% 
from DMSO, mp 3 1 5 °C Rc = 0 .62 ( 6 :4 hexane / ethylacetate), IR (KBr, cm'
l) 1 643 (CO), 
25 
2220 ( ) , 3425 H ,  IH-NM R [OM 0-d6, 200 M Hz) :  8 ppm) 6 9  (s , I H), 7 30-7.8 (m 
5 H, aromatic), 7 .90 (d I H  J = 8 6 Hz, H aromatic), 8 05- 06 (m, 2 H), 1 2 70 (bs, I H , NH); 
1 R  [0 r 0-d6, 200 M Hz) " (8, ppm) 95 5 (C3 ), 1 04 5 (C5),  1 1 7 .0  (C ) 1 27 8- 1 36 7 (Ar-
), 1 5 0 ( 6 , 1 5 1 2 ( 0 o f  pyridine , 1 62 2 (C4), Anal Calcd for C I6H ION20S (278 33 )  C, 
69 04 ; H, 3 62, , 1 0 06, , I I  52 %, found C, 68 .70,  H, 3 .63 ,  N, 1 0 0; S, 1 1  50  % 
4-(Thiopltelt-2-yl)-6-(p-c!tloroplzell} l)-3-cyalto-2 ( l H}-pyridill olles (82e) : Pale yellow 
cl)'Stal s '  yield 2% [rom OM 0, mp 342-343°C; Rr = 0 .32  (6 .4 hexarte / ethylacetate), IR 
(KBr, em- I) 1 660 (CO), 2220 (CN) 3430 (NH); I H-NMR [OMSO-d6, 200 M Hz] . (8, ppm) 
6 9  (s, 1 H,  -5), 7 .29-7 34  (m, I H, aromatic), 7 . 57-7.62 (d, 2H ,  J = 8 . 6  Hz), 7 88 -7.93 (d,  2H, 
J = 6 Hz), 7 9  -8 .07 (m 2H , 2-thienyl), 1 2 . 74 (bs I H, NH); 13C-NM R [(OMSO-d6), 200 
MHz]:  (8, ppm) 1 04 . 8  (C-5 ), 1 1 6 . 9  (CN) 1 1 6.0  (C-3) 1 28 . 7 - 1 36 .7  (aromatic carbons), 1 50.2 
(C-6), 1 50 7 (C-2), 1 62 3  (C-4). Anal . Calcd for C l6H9N20ClS (3 1 2 .77) :  C,  6 1 .44 ;  H, 2 90; N, 
96, 1 0 25 0'0 found C, 6 1 .40'  H ,  2 .90' N, 8 .94, S ,  1 0.30  % 
4-(2- Trijluorometlzylplzeltyl}-6-plzellyl-3-cyano-2 ( l H)-pyridinolles (82j):  Yellow crystals; 
yield 0% from OMSO mp 3 06-3 07°C- Rr = 0 .34 (6 :4 hexarte / ethyl acetate), IR (KBr, em- I) 
1 637  (CO) 2349 (CN) 3446 (NH); IH-NMR [DMSO-d6, 200 M Hz) :  (8, ppm) 3 82 (s, 3H, p­
OCH3) 6 84 (s, I H  C-5) ,  7 .02-7. 1 0  (d, 2H, J = 9 .0 Hz), 7 .67-7 .70 (d, 2H,  J = 4 .4  Hz), 8 75-
8 78 (d, 2H, J = 4 4 Hz) 1 2 . 8 1 (bs , I H  NH); 13C-NMR [DMSO-d6, 200 M Hz] : (8, ppm) 55 .6  
(OCH3 1 0-+ 8 (C-5) 1 1 6. 1 (CN), 1 1 4 .4 , 1 24 . 1 1 29 .6 ,  artd 1 57 .  1 (aromatic carbons at C-6), 
1 22.6,  1 50 2 ,  artd 1 52 .0  (aromatic carbons at C-4), 1 43 .6 (C-6), 1 6 1 . 8 (CA), 1 6 1 . 9 (C-2). 
Anal Calcd for CI9H I I 20F3 (340. 3 0). C 67.06; H ,  3 .26; N, 8 23 %, found: C, 67.4, H, 3 .30, 
, 8 . 30  % 
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4-(Pyridill-4 '-yl)-6-(p-metltoxyplzellyl)-3-cyallo-2(1 H}-pyridinolles (82g): Yello\ crystals '  
yield 600� from D f 0 mp 329- 30°C; Rr = 0 236 (6 4 hexane / ethylacetate)· IR (KEr, cm­
I) 1 640 CO), 2222 ( ), 344 H I H-NMR [DM 0-d6, 200 M Hz) : 8, ppm 6 .87 (5, 1 H ,  
H-5 , 7 45- 00 (m, 9H ,  aromatic), 1 2  9 1  (bs 1 H NH), LlC_ MR [DMSO-d6, 200 M Hz] (8, 
ppm) 1 06 3  ( -5) 1 1 6 2  (C ), 1 22 .0 (CF3), 1 25 .7- 1 32 .3  (aromatic carbons), 1 40. J (C-6), 1 5 8 4 
(C-4 '). 1 6 1  3 (  -2) Anal. Calcd for C 1  H 13N302 (303 .3 1 ) · C 7 1 . 28 ·  H ,  4 3 2;  N, 1 3 . 85  % , 
Found , 7 1 4 ,  H 4 . 1 . N, 1 3 . 8  %. 
4-(p- Tolyl)-6-(p-c!tloroplzeltyl)-3-cyalto-2(1H}-pyridinofles (821t) : Yellow crystals; yield 
oo� from D 1 0, mp 3 1 2-3 1 3 °C; Rr = 0 1 80 (6 "4 hexane / ethylacetate); IR (KBr, em- I) 2 349 
(C , 1 636  (CO) 3433  (NH), IH-NM R [DMSO-d6, 200 M Hz) : (8 ppm) 2 3 7 (s, 3 H, CH3), 
6 83 (5 , 1 H ,  H -5) ,  7 . 3 3 -7 .92 (m 1 2 H, aromatic), 1 2 . 8 1 (bs, I H, NH); 13C-NMR [DM SO-d6, 
200 M Hz] (8, ppm) 1 07 .2  (C-5) ,  1 1 7.2  (CN), 1 1 7.0  (C-3 ) , 1 28 .9- 1 3 6.6  (aromatic carbons), 
1 4 1 2 (C-6), 1 60 2  C-2), 1 62 . 8  (C-4) ;  Anal. Ca1cd for CI9H 13ClN20 (320 .77) :  C,  7 1 . 1 4 , H, 
4 08,  , 8  73 0 0 found : C, 7 1 . 20 H 4 .03 ; N,  8 .67 % 
4-Pltenyl-6-(p-chloropltenyl)-3-cyalto-2(1H)-pyridiltones (82i) : yellow crystals; yield 80% 
from ethanol ,  mp 3 05-306°C; Rr = 0.22 (6 :4 hexane / ethylacetate); IR (KBr, ern- I) 22 1 6  (CN), 
1 63 5  (CO). 3446 (NH); IH -NMR [DMSO-d6, 200 M Hz] :  (8, ppm) 6 . 87  (s I H  H-5), 7 .52-7 .95 
(rn, 1 0H aromatic), 1 2  8 1  (bs, 1 H ,  NH), 13C-NMR [DMSO-d6, 200 M Hz] . (8,  ppm) 1 07 .4 (C-
5) ,  1 1 7 I (C ), 1 1 7 0  (C-3 ) ,  1 2 8 9- 1 36 .7  (Aromatic carbons) 1 5 1 . 2 (C-6), 1 60 .3  (CO of 
pyridine), 1 62 8 (CA); Anal . Ca1cd for CisHuCIN20 (306 .75) :  C, 70 .48;  H ,  3 . 6 1 ; N ,  9. 1 3  %; 
found :  C, 70 80;  H ,  3 .62, N,  9 . 1 3  %. 
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2 .2 . 1 l ethod A (fhe Pota ium alt Method) 
1-(2 '�3 '�4 '�6 I� Tetra-O-acetyl-p-D-glycopyrallo yl)-3-cyallo-4,6-subistituted-2-
pyridillolle (83a-e) alld (8 a-e) :  To a solution of  4 6-disubstituted-3 -cyano-2( 1 H)­
pyridmones (0 0 1  mol) in aqueous KOH [0 .56  g (0.0 1  mol)] in 6 ml distilled water, a solution 
of 2, ,4 ,6-tetm-O-acetyl -a-D-hexapyranosyl bromide (0. 0 1 1 mol,  4. 1 2  g) in acetone 30 ml 
was added The reaction mixture was st irred at room temperature until the reaction was 
Judged completed by TL (4-6h)- 30  ml o fCH2Ch was then added. The organic layers were 
dried 0\ er a� 0-\, fi l tered and the organic  solvent was removed under reduced pressure at 
room temperature to alTord the crude nucleoside products The residue was recrystall ized 
from ethanol to give the n ucleosides (83a-e) (Scheme 1 8 ) and (87a-e) (Scheme 2 1 )  
1.2 .2.2 M ethod B (The Si l  I Method) 
1 -(2 '� 3 '� 4 '� 6 /� Tetra-O-acetyl-p-D-glucopyranosyl)-3-cyallo-4-(thiophe"-2-yl)-6-(4 � 
chlorophellyl)-2-pyridillolle (83d) :  A mixture of 2-pyridinone (82d) (0 0 1  mol), 1 , 1 , 1 ,3 3 ,3 
hexamethyldis i lazane  (HMDS, 60 mL) ammonium sulfate (0. 1 25 g) and drops of 
chlorotrimethylsi lan e  was heated under nitrogen for 4-8  h .  Excess HM DS was removed by 
distil lation, and the residue was dried under a reduced pressure for 6 h. The resulting 
intermediate bis-silyl derivative (84) was dissolved in anhydrous MeCN (20 mL) and a 
solution of  a 1 ,2 3 4,6-penta-O-acetyl-a-D-glycopyranose (0 .0 1 mol ,  3 9 1  g) in 20 mL of 
MeCN was added with stirring. The mixture was cooled to 5 °C during the subsequent 
addition ofTMSOTf (2 1 7  mI ,  0 .0 1 5  mol). The stirring at room temperature was continued for 
1 6- 1 8h until the reaction was completed as observed by T LC analysis ( 1 : 1  chloroform; 
acetone) The m ixture was di luted with CHCh ( 1 50 mL), and the organic solution was washed 
2 8  
\\ ith a saturated aH 03 solution (50 mL) and then H20 (2x50 mL) The organic layer was 
dried anhydrous a2 04) The solvent was removed under a reduced pressure and a crude 
product thus obtained was PUI; (jed by column chromatography on a si l ica gel column using 5% 
1eOH in H h as an eluent to give the pure product (83d) in a yield of  6 1  % (Scheme 1 9) 
1-(2 '�3 '�4 '�6 I� Tetra-O-acetyl-p-D-gllicopyranosyl}-3-cyallo-4 6-dipltellyl-2-pyridillolle (83a) 
\Vhite crystal ; }'leld 66°'0 (method A), mp 1 93 °C, from ethanol;  Rr = 0.48 (64 hexane / 
ethyl acetate) I R  (KBr, em- I ) 1 600 C-2), 1 752 (acetyl carbonyl CO) 2220 (CN), [a]25 = 25 40 
(c = 4 92 mg mL, chloro form), IH-NMR [CDCb, 200 tvfHz] : (8, ppm) 1 . 9 1 -2 .07 (4s, 1 2H, 
4CH3CO), 4 03-4 25(m 3 H  H-5" , H-6"a H-6"b), 5 .22 (t, I H, H-4"), 5 4 1 -5 .47 (m, 3 H, H-
2" ,H-3" , 6 3 3 (d, I H  H- l " , ] = 7 .8  Hz), 7 .49-8 .00 (m, 1 0H,  aromatic), 13C-NMR [CDCh, 200 
tvfHz] (8, ppm) 20 3 -20 5 (4CH3), 62.0 (C-6'), 68 .3  (C-4'), 70.3 (C-2 ') 72 .6  (C-3 '), 72. 8(C-5 '), 
94 3 (C- l ") 94 3 (C-5) ,  1 1 3 9 (C-3), 1 1 5 . 5  (CN), 1 27 .2- 1 36 .8  (aromatic carbons), 1 57 .3  (C-6), 
1 57 .  (C-2) 1 62 3 (C-4) 1 6  . 9- 1 70.6 (four acetoxy carbonyl carbon) Anal Calcd for 
C32H30 2010 (602 59)  C, 63 . 78 '  H, 5 .02; N, 4.65 %, found: C ,  64 .00; H ,  5 , 1 4 ; N,  4 .6 1 %. 
1-(2 '�3 '�4 /�6 I� Tetra-O-acetyl-p-D-gllicopyrallosyl)-3-cyano-4-(o-tolyl)-6-phellyl-2-
pyridinolte (83b) Wh ite crystals' yield 65%, (method A); mp 1 89 - 1 90°C, from ethanol ;  Rr = 
0.3 8 1 6 4  hexane I ethylacetate), IR (KBr, ern- I) 1 659 (C-2), 1 765 (acetoxy carbonyl) 2352 
(C , [  a]l5 = 26  1 ° (c = 3 84 mg/ml,  chloroform), IH-NM R [CDCb, 200 M Hz] :  (8, ppm) 1 .93-
2 08 (4s ,  1 2H ,  4CH3) ,  2 28 (s ,  3H o-CH3), 4 .00 (m, I H, H-5 ')  4 .25-4 ,27 (m,  2 H, H-6"a, H-
6"b) 5 23-5 .47 (m 3H,  H-2" , H-3", H-4"), 6. 32-6 .36 (d ,  I H, H- l /1 ,  ] = 7 .8  Hz), 7 .25-8 .05 (m, 
1 0H, aromatic), 13C-NMR [CDCb, 200 M Hz] :  (8, ppm) 20. 1 (ortho-CH3), 20 .8 (4 CH3) ,  62.3 
(C-6"), 68 6 (C-4/1) 70.6 (C-2") ,  72 .9  (C-3 "), 73 .0  (C-5/1), 94.7 (C- l ") ,  96. 1 (C-5),  1 1 4 .0  (C-3), 
1 1 6 5  (C ) , 1 26 4- 1 36. 9  (aromatic carbons), 1 57 . 8  (C-6), 1 5 8 . 5  (C-2) ,  1 62 0 (C-4), 1 70.9 (four 
29  
acetoxy carbonyl carbon),  Anal Calcd for C33H32 2010 (6 1 6 6 1 )  C, 64 2 , H 5 .23 , , 4 54 %, 
found , 64 50,  H, 5 2 ,  4 70 % 
1-(2 '�3 '�4 '�6 If- Tetra-O-acet)'l-p-D-glucopyraltosyl)-3-cyallo-4-(thioplten-2 '-yl)-6-pltefl)'l-
pyridillolte (83c) : White clystals · yield 72%, (method A), mp 1 8 - 1 8 9°C, from ethanol, Rr = 
0 92 1  (6 4 hexane / ethyl acetate), IR (KBr em-I ) 1 680 (CO), 1 752  (acetoxy carbonyl), 2354 
� I C ) [ a] = 7 . 1 ° (c = 4 28 mg/ml,  chloroform), H-NMR [CDCh 200 M Hz] :  (8, ppm) 1 92-
2 07 (4 , 1 2H 4 H3), 4 .06 (m, 1 H , H-51) , 4 .2 1 -4 22 (m, 2H, H-6"a H-6"b) 5 1 8-5 50 (m, 3 H, 
H-2I,H-3 ", H-4") 6 29 (d, 1 H, H- l "  J = 9 .0  Hz), 7.20-7. 56 (m 5 H, aromatic), 7 .69 (s, I H, H-
5) ,  7 9  - 06 (m 2 H, thienyl H-2 3 )  I3C-NMR [CDCh 200 M Hz) " (8, ppm) 20.6-20 7 
(4CH]) 62 0 (C-6"), 68  4 (C-5") 70.3 (C-4") 72 .98(C-3"), 73 .0  (C-2") ,  9 1  8 (C5 ), 94 .4 (C- l " ), 
1 1 4 2  (C-3 ), 1 1 4 5  (CN), 1 27 . 3 - 1 3 7 .2 (aromatic carbons) 1 48 . 6  (thienyl C-2 ), 1 58 .0  (C-6), 
1 62 9 (C-2), 1 68 .9  1 70 .9  1 70 .4  and 1 70 .6  (four acetoxy carbonyl carbon); Anal .Calcd for 
C30H:! 2010 (608.62) ·  C, 59 .20· H ,  4 .64; N, 4 .60; S, 5 .27  %,  found: C, 60.20; H 4.70; N, 
4 60 S , 5 20  %. 
1 -(2 '�3 If 4 '�6 ,'- Tetra-O-acetyl-p-D-glucopyraflosyl)-3-cyaflo-4-(tlt ioplten-2-yl)-6-( 4-
chloropltellyl}-2-pyridiflo lte (83d) :  White crystals ;  yield 48% (method A), 6 1  % (method B), 
mp 1 55 - 1 5 6°C, from ethanol ,  Rr = 0.625 (6 :4 hexane / ethylacetate) IR (KBr, em- I) 1 64 1  (C-
2), 1 75 2  (acetoxy carbonyl) ,  2 3 3 0  (C ); [a]
25 = 1 7 .9°  (c = 9 .2 mg/ml,  chloroform), l H-NM R 
[CDCh, 200 M Hz) "  (8, ppm) 1 93 -2 .07 (4s ,  1 2 H, 4CH3) ,  4 .00 (m, 1 H ,  H-5") ,  4 . 1 9-4 .25 (m 2H, 
H-6"a, H-6"b) 5 .20-5 .25 (m, I H  H-4") 5 .3 9-5 .45 (m 2H, H-2", H-3 " ) ,  6 .25-6 .30 (d, I H, H­
I ", J =  8 2 Hz), 7 1 9 -7 .22  (d, 2H, J = 3 . 8  Hz), 7 .45 -7. 5 1 (m, I H, thienyl H-5 ) ,  7 . 56-7.59 (d, 2H 
CH , J = 4 .2 Hz), 7 .63 (s, I H, H-5) ,  7 .94-7.99 (m, 2H ,  thienyl H-2 , H-3); 1
3C-NMR [CDCb, 
200 M Hz] (8, ppm) 20.6-20.7 (4CH3), 6 1 . 7 (C-6"), 67. 1 (C-5"), 67 .8  (C-4"), 70. 9(C-3"), 7 1 . 7 
30 
(C-2") 95 .0  (C- 1 "), 9 1 . 9 (C-5), 1 1 3 .9  (C-3), 1 1 4 .5 (CN), 1 28 . 5 - 1 3 7 .2 (aromatic carbons) 
1 4  7 (C-6), 1 5 6 7 (C-2) ,  1 63 . 1 (C-4) , 1 68 .9 ,  1 70.2 1 70. 3 and 1 70 . 4  ( [our acetoxy carbonyl 
carbon) Anal Calcd for C30H27CIN201OS (643 .06): C 56.03 ; H, 4 . 23 ;  N, 4.36;  S, 4.99 %, 
found' , 5 6.00; H 4 .20;  N, 4.2 1 ;  S, 4.99 % 
1 -(2 '�3 '�4 '�6 I� Tetra-O-acetyL-p-D-g[ucopyranosyl)-3-cyano-4-[2_(trif/uoro111 et/tyl)-p/teny/J-6-
p/te/1) /-2-pyridif1olle (83e) :  White crystals' yield 3 0% (method A); mp 1 67 - 1 68°C, from 
ethanol ,  Rf = 0.86 (6 :4 hexane / ethylacetate), IR (KBr, em- I ) 1 660 (C-2), 1 760 (acetoxy 
carbonyl) 2400 (CN); [ af5  = 9.5° (c = 8 .4  mg/roL, chloroform); I H-NMR [CDCb, 200 M Hz]: 
(8, ppm 1 . 9 1  2 . 05 , 2 .06, 2 .08 (4s, 1 2 H, 4CH3) 4 .05-4. 1 1  (m, I H , H-5 " ) ,  4. 22-4 .25 (m, 2 H, H-
6"a,H-6"b), 5 . 1 8 -5 .2 7  (m, I H, HA"), 5 .42-5 .47 (m, 2H,  H-2" ,  H-3"),  6. 3 3 -6 .37  (d, 1 H, H- l " , J 
= 8 Hz) 7.26-8 . 0 1 (m 9H,  aromatic); 13C-NMR [CDCb, 200 M Hz] :  (8 ppm) 20.5-20.6 (4s, 
4CH3) ,  62 . 0  (C-6"), 68.3 (C-5"), 70.3 (C-4"), 72 .7 (C-3"), 94 . 2  (C-2" ), 94.4 (C- 1 ") ,  1 1 3 .6 (C-
5) ,  1 1 5 . 3  (C-3)  1 1 6 .5  (CN), 1 26. 1 (CF3), 1 27 .3 - 1 3 9 . 3  (aromatic carbons), 1 62 .3  (C-6), 1 55 .7 
(C-2) 1 5 8 . 4  (C-4) 1 68 .9- 1 70.6 (four acetoxy carbonyl carbon); Anal. Calcd for C33H29F3N201O 
(670.59) '  C,  5 9 . 1 1 ; H ,  4 . 3 6' N,  4 . 1 8  %, found: C, 59 . 8 ;  H ,  4 .30 ;  N,  4 . 1 2  %. 
1 -(2 '�3 '�4 r�6 "- Tetra-O-acetyL-p-D-galactopyra nosyl)-3-cyano-4,6_diphellyl -2-pyridinone 
(8 7a) : White crystals; yield 49%, mp 1 74 - 1 75°C, from ethanol ,  Rc = 0.3 9 1  (6:4 hexane / 
ethylacetate), IR (KBr, cm- I )  1 642 (C-2), 1 748  (acetoxy carbonyl) ,  2225 (CN); 
[ a]25 = 2 1 . 8° (c = 3 .2  mg/mL, chloroform); I H-NMR [CDCh, 200 M Hz] : (8, ppm) 1 . 88-2.22 
(4s ,  1 2H ,  4CH3) ,  4 . 1 7-4 .28  (m, 3 H, H-5 " , H-6"a, H-6"b), 5 . 2 1 -5 . 28  (m, I H, H-4") 5 . 5 1 -5 .74 
(m, 2 H, H-2", H-3 " ) 6 .27-6. 3 1 (d, I H, H- I " , J = 8 Hz), 7 . 50-7.70 (m, 8 H ,  aromatic), 7.66 (s, 
I H, H-5),  8 .04-8 .09 (m, 2H ,  aromatic); 13C-NMR [CDCh, 200 M Hz] : (8, ppm) 20.5 , 20.6, 20.6 
and 20.7 (4C H3), 6 1 . 8 (C-6") ,  67.2 (C-5"), 67.9 (C-3"),  70.9 (C-4"), 7 1 . 8 (C-2"), 94.0(C-5), 
3 1  
94 9 (  - I "), 1 1 4 .0 ( -3 1 1 5 4  C ) 1 27 3 - 1 36 8 (aromatic carbons), 1 5 7 2 (C-6), 1 5 7 8 (C-
2) 1 62 4 -4), 1 6  9, 1 70 .2 ,  1 70 3  and 1 70.4 (four acetoxy carbonyl carbon) Anal Calcd for 
nH30 2010 (602 59)  63 7 , H ,  5 02, , 4  65 % found C, 64 20; H ,  5 20, , 4  70 % 
1-(2 I�J '�4 '�6 "- Tetra-O-aeetyl-p-D-galaetopyrallosYl}-J-eyano_4_(m_to l 1)-6-phellyl-2-
pyridiltolle (8 b) : White crystals '  yield 74% mp 1 96- 1 97°C, £i-om ethanol;  Rr = 0.43 
( 6 4 hexane ethyl acetate) IR  (KEr, em- I) 1 652 (C-2), 1 748  (acetoxy carbonyl), 2235 (CN) 
[a]25 = 7 -0  (c  = 4 0  mg ml ,  chloroform); IH-NM R [CDCb, 200 M Hz] . (0, ppm) 1 .93-2 08 (4s, 
1 2H 4CH3) 2 2  (s, 3 H, ortho-CH3), 4 . 1 7-4 .28 (m, 3H H-5" , H-6"a, H-6"b), 5 .2 1 -5 .2 8  (m, 
I H  H-4" J = 3 4), 5 5 1 -5 53 d, I H, H-3" J = 3.8 Hz) ,  5 .64-5 . 74 (dd, 1 H ,  H-2", J = 8 2 Hz), 
6 27-6 3 1  (d, I H, H- l "  J = 8 .2  Hz), 7 .26 (s, I H, H-2'), 7 .32-7 .90 (m 7H, aromatic), 8 07-8 09 
(m, 2 H  aromatic) 13C-NMR [CDCb, 200 M Hz] :  (0, ppm) 20.5 -20 7 (4CH3), 2 1  4 (O-CH3), 
6 1  8 tC-6"), 67 2 (C-5"), 67.9 (C-3 ") 70.9 (C-4") ,  7 1 .7 (C-2"), 94 .0 (C- l ") ,  94.9 (C-5), 1 1 4 0  
(C-3), 1 1 6 5  C ), 1 25 2 - 1 3 8 8 (aromatic carbons), 1 57 . 8  (C-6), 1 5 8 . 5  (C-2) ,  1 62 0  (C-4) 
1 70 9 (four acetoxy carbonyl carbon); Ana1 .Calcd for C33H32N2010 (6 1 6 .6 1 ): C, 64.28 ;  H,  5 . 23 ;  
N,  4 .54 0,-0, found C 64 20' H ,  5 . 1 4 ; N,  4 .6 1 % 
1-(2 '�3 ';4 '�6 '� Tetra-O-aeetyl-p-D-galaetopyrallosyl}-3-eyallo-4-(thiophen-2-yl)-6-phenyl­
pyridillolle (8 7e) : white crystals ' yield 68% mp 2 1 6-2 1 7°C, from ethanol ;  Rr = 0 33 
( 6 "4 hexane ethylacetate) IR (KBr, em- I) 1 650  (C-2) 1 753 (acetoxy carbonyl), 224 1 (CN); 
[aJ25 = 8 . 8° (c = 4 0 mglrnl, chloroform), IH NMR [CDCh, 200 M Hz] .  (0, ppm) 1 . 8 8 , 2 .03 
2 04 and 2 22 (4s, 1 2H ,  4CH3), 4 . 1 6-4 .23  (m, 3 H, H-5" , H-6"a,H-6"b), 5 . 1 9-5 .26 (dd, I H  H-
4" ,  J = 3 6 Hz), 5 .49-5 . 5 2  (d ,  I H, H-3" ,  J = 3 .6 Hz), 5 .63 -5 .73 (dd, I H, H-2" ,  J =8 .2  Hz), 6.24-
6 28 (d, I H  H- l " , J =8 2 Hz), 7 . 5 1 -7 . 56  (m, 3 H, aromatic), 7 . 5 8 -7 . 59  (m, I H, th ienyl H-4), 
7 .69 (s , 1 H  H-5), 7 .96-7 98  (m, 1 H, thienyl H-3), 8 .02-8 .07 (m, 2 H, aromatic) 1
3C-NM R 
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[CDCI3 200 M Hz] :  (8, ppm) 20 5 -20 7 (4CH3), 6 1 . 8 (C-6") 67 .2  (C-5"), 67 .8 (C-3"), 70.9(C-
4"), 7 \  7 (C-2 "), 9 1 . 6 (C- 1 " ), 94 .9  (C5 ), 1 1 4 . 1 (C-3 ), 1 1 4 . 5  (CN) , 1 27 . 2 - 1 37 .2  (aromatic 
carbons), 1 48 5 (thi enyl C-2 ), 1 57 .9 (C-6), 1 62 .9  (C-2), 1 68 . 9  1 70 .2 , 1 70.3 , and 1 70.4 (four 
acetoxy carbonyl carbon); Anal Calcd for C30H28N20lOS (608 . 62) :  C,  59 .20;  H, 4 .64; N, 4 .60; 
5 .27  % found C, 60. 6; H,  4 .7 ;  N, 4 .6; S,  5 . 3  % 
1-(2 '�3 '�4 ';6 "- Tetra-O-acetyl-p-D-galactopyraflosyl)-3-cyaflo_4_(thiophell-2 CylJ-6-(p­
cltioroplteltyl)-2-pyridillolte (8 7d) : white crystals ;  yield 48%,  mp l 55 - 1 5 6°C, from ethanol, 
Rr = 0.63 (6:4 hexane / ethylacetate), IR  (KBr, em-I) 1 590 (C-2), 1 760 (acetoxy carbonyl) 
223 0 (C ). [ a]�5 = 8 . 7° (c = 4 .0  mg/ml, chloro fo rm); IH NMR [CDCb, 200 M Hz) :  (8, ppm) 
1 . 92 2 04 2 .06 and 2 .23  (4s ,  l 2 H ,  4CH3), 4 . 1 7-4 .26 (m, 3 H, H-5 " , H-6"a,H-6"b), 5 . 20-5 .27 
(dd, 1 H  H-4 " ,  J = 3 .2 Hz), 5 . 5 1 -5 . 52  (d 1 H, H-3" J = 3 .4 Hz), 5 .64-5 . 73  (dd, l H, H-2" ,  J = 
8 . 2  Hz) 6 20-6.25  (d l H, H- 1 " , J = 8 .2  Hz), 7 . 49-7 .53  (m, 2H,  aromatic), 7 . 5 6-7.6 1 (dd, 1 H, J 
= 3 .4 Hz, aromatic) 7 .65 (s, 1 H, H-5),  7 .98 -8 .02 (m, 3H ,  aromatic); 13C-NMR [CDCh, 200 
M Hz) :  (8, ppm) 20.6-20.7 (4C H3), 6 1 . 7 (C-6"), 67. 1 (C-5 "), 67 .8  (C-3 "),  70 .9  (CA"), 7 1 . 7 (C-
2") 9 1 . 9 (C-5)  95 .0  (C- l "), 1 1 3 . 9  (C-3 ), 1 1 4 . 5  (CN), 1 28 . 5 - 1 37 .  1 (aromatic carbons) ,  1 56 .7  
(C-6) 1 63 . 1  (C-2), 1 68 .9  (C-4) 1 70 .4 (four acetoxy carbonyl carbon). Anal . Calcd for 
C30HnCI 2010S (643 .06): C, 5 6 .03 ; H ,  4 . 23 ;  N, 4 . 36 ;  S,  4 .99  %; found :  5 6. 1 0, H, 4 .22;  N, 
4 . 3 5 ;  S 4 .90  %. 
1-(2 '�3 II 4 '; 6 'C Tetra-O-acetyl-p-D-galactopyraflosyl)-3-cyaflo-4-(p-trijluorometltyl-pIt eflyl)-
6-pheltyl-2-pyridiflone (8 7e) : white crystals ;  yield 48%, mp l 55 - 1 5 6°C,from ethanol; Rr = 
0 63 ( 6:4 hexane / ethylacetate), IR (KBr, em-I ) 1 63 5  (C-2),  1 743 (acetoxy carbonyl) ,  2353 
(CN) [ a]25 = 1 4 .4°  (c = 8 .0  mg/ml ,  chloroform); I H-NMR [CDCh, 200 M Hz) : (8, ppm) 2.20 
(m, 1 2H ,  4CH3),  4 . 1 7A.25 (m, 3 H, H-5" ,  H-6"a, H-6"b), 5 .26-5 . 27  (dd, 1 H, H-3 " , ]  = 3 .4 Hz), 
3 3  
5 5 1 -5 . 5 3  (d I H , H-4" ,  J = 2 6 Hz) 5 . 64-5 . 73 (dd, 1 H, H-2", J = 8 .2  Hz), 6.27-6 3 1  (d, I H, H­
j " , J = 8 2 Hz), 7 . 52-7 . 5 5  (m, 3 H , aromatic) 7 .60 (s , I H, H-5 ) 7 .7 8-7 80  (m, 4H ,  aromatic), 
8 04-8 0 (m, 2 H  aromatic) 13C_NM R [CDCb, 200 M Hz]: (8, ppm) 20 .5-20 .7  (4CH3), 6 1 . 8 
(C-6"), 67 .2 (C-5" )  67 . 8 (C-3 "), 70. 9 (C-4"), 7 1 . 8 (C-2"), 94 .0  (C- l "),  95 .0(C-5),  1 1 5 .0  (C-3 ) 
1 1 5 . 2 (C ) , 1 26 . 1 ( CF3) ,  1 27. 3 - 1 36 . 5  (aromatic carbons), 1 55 .6 (C-6), ] 5 8 .4  (C-2), 1 62 .0 (C-
4) 1 68 .9 - 1 70 .4 (four aceto y carbonyl); Anal.Calcd for C33H29F3N2010 (670.59): C, 59 . 1 1 ;  H ,  
4 36; ,4 .  1 8%,fo und:C,60 . 1 · H ,4 . 3 8 ;N,4. 1 2%. 
3 4  
2 .3 General Proced ure for N ucleoside Deacylation 
2 .3 . 1 Method A ITransesterificat ion-Saponification Using Saturated Methanolic 
Ammonia) 
Dry gaseous ammonia was passed through a solution o f  acetylated nuc leoside (83 a-e) (0.5 g) 
in dry meUlano! ( 1 0  mL at O°C for about 0.5 h. The reaction mixture was stilTed at O°C until 
complete as shown by TLC; the residue was puri fied by Dash  chromatography eluting with 
2°� EtOH in CH}Cb to give a \ hite c lystalline product (8 Sa-e). 
2.3.2 Method B (Transesterification-Saponification Usin g Triethvlam ine) 
Acetylated n ucleoside (87a-e) was dissolved in a mixture o f  (MeOH/I-hO/Bt3N) in ratio o f  
( 1 : 1 :  1 )  and the mixture was stined over night at room temperature. The reaction mixture was 
monitored by TLC (2% methanol and 98% CH2Ch) and stin-ing was continuous until the 
reaction completed. The solvent was removed under reduced pressure at room temperature 
and the residue was purified by column chromatography eluting with 2% BtOH in CH2Ch to 
give a white crystalline product o f  the deacetylated nucleosides (88a-d). 
1-(fJ-D-glucopyranosyl)-3-cyano-4,6-diphenyl-2-pyridinone (85 aj : White ClYStalS ; yield 5 2% 
(method A) mp 1 82°C, from methanol; Rf = 0.35  (CH2Ch), IR (KBr, cm-1 ) 1 5 90 (CO), 223CJ 
� 1 (CN) , 3 430  sugar-OH; [ar = 1 1 6 . 8 °  (c = 1 0 .4  mg/ml ,  methanol); H-NM R [DMSO-d6, 200 
MHz]:  (0, ppm) 3 .26-3 . 67 (m, 6H, H-2", H-3 " , H-4" , H-5",  H-6"a,H-6"b), 4 . 5 7 -5 .43 (4 OH 
exchagab1e with D20), 6. 1 3 -6 . 1 6  (d, 1 H, H- 1 " , J = 7 . 4  Hz), 7 . 5 1 -7 .60 (m, 6H, aromatic ) ,  7 .73-
7.76 (m, 2H, aromatic), 7 . 8 8  (s, I H, H-5 ), 8 .22-8 . 2 7  (m, 2H, aromatic); 13C-NMR [DMSO-�, 
200 M Hz] : (0, ppm) 60.6 (C-6'), 69.7 (C-5'), 72 . 9  (C-4'), 77 (C-3 '), 78 .0(C-2 ') 96 .6 (C- 1 "),  
92 8 (C-5 ) 1 1 4 . 9  (C-3 ), 1 1 5 .0  (CN), 1 27 . 6 - 1 36 .5 (aromatic carbons), 1 5 6 .8 (C-6), 1 57 . 4  (C-2), 
1 62 .9 (C-4). Anal. Calcd for C2.Ji22N206 (434 .44) :  C, 66. 35 ;  H, 5 . 1 0 ;  N, 6.45,  found: C, 65.99;  
H 4 . 9 8 ;  N, 6 . 4 1 %� 
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1-(P-D-glucopyrallosyl}-3-cyalto-4-(m-tolyl)-6-phenyl_2_pyridinolle (85b): White crystals '  
yield 63 °'0 (method A); mp 1 63°C, fi.-om methanol; Rf = 0.5 1 (CH2Ch), IR (KEr, crn- I) 1 5 85 
(CO), 2450 (C ), 3400 sugar-OH ' [ a]25 = 88°  (c  = 6 .52 mg/ml, methanol), IH-NM R [DMSO­
d6 , 200 1 Hz] (8, ppm) 2 .52  (s 3 H  CH3), 3 . 3 6-3 .66 (m, 6H, H-2" H-3" ,  H-4",  H-S " , H-6/1a,H-
6/1b), 4 .65 -5 .27(4 OH, exchagable with D20), 6. 1 2-6. 1 5  (d, I H, H- 1 /1 ,  J = 7 .8  Hz), 7 .39-7 .57 
(m, 7H,  aromatic), 7 . 8 7  (s ,  1 H, H-5 ), 8 .24-8 .28 (m, 2H,  aromatic); 13C-NM R [DMSO-d6, 200 
1Hz] (8 ppm) 2 1 . 7 (s CH3), 6 1 .0 (C-6/1) 68 . 8 (C-5 /1), 70.6 (C-4"), 74 .2 (C-3/1), 77 . 1 (C-2/1) ,  
93 . 4  (C- l /1), 97 .8 (C-5 ), 1 1 5 .4 (C-3 ), 1 1 5 . 7  (CN), 1 26 .4- 1 39 .0 (aromatic carbons), 1 5 7.5 (C-6), 
1 57 .9  (C-2), 1 63 . 7  (C-4 ). Anal. Ca1cd for C25H2�206 (448 .47) :  C, 66.95 ;  H, 5 . 39; N, 6.25 %, 
found' C 66. 89 ;  H, 5 . 3 7 '  N, 6 .3 1 %. 
1-(P-D-glucopyranosyl}-3-cyano-4-(thiophen-2-yl)-6-phenyl-2-pyridinone (85c): White 
crystals '  yield 74% (meth od A); mp 2 1 9°C from methanol; Rr = 0 .34 (CH2Ch), IR (KEr, em-I) 
1 595 (CO) 2300 (CN) , 3 445 sugar-OH;  [a]25 = 202° (c = 8 .4 mg/m1 ,  methanol); IH NM R 
[DMSO-d6, 200 M Hz] :  (8, ppm) 3 .25 -3 .68 (m, 6H, H-2/1, H-3/ 1 ,  H-4/1 ,  H-S " , H-6/1a, H-6/1b), 
4 . 59-5 45 (4 OH, exchagable with D20) 6 . 1 1 -6. 1 5  (d, 1 H, H- l /l ,  J = 7 . 8 Hz), 7 . 32-7 . 37  (dd, 
1 H, thienyl H-5 , J = 3 . 4  Hz), 7 . 54 -7 .56  (m 3 H, aromatic), 7 .97  (s , 1 H, H-5 ), 7 .98-7 .99 (dd, 1 H, 
thienyl H-3 , J = 1 . 2 Hz), 8 .03-8 .06 (dd, l H, thienyl H-2, J = 1 . 2 Hz ), 8 .22-8 .27 (m, 2H,  
aromatic); 1 3C-NM R [DMSO-d6, 200 MHz] :  (8, ppm) 60.5 (C-6/1), 69 .6 (C-5/1) , 72 .7  (C-4/1) 
76.9(C-3 /1), 78 .0  (C-2/1 ), 90A (C-3 ) 96.7(C- 1 /1) , 1 1 3 . 4  (C-5), 1 1 5 .3 (CN), 1 27 .6- 1 36.5 
(aromatic carbons), 1 48 . 3  (C-6), 1 57 . 4  (C-2), 1 63 . 5  (C-4). Anal . Ca1cd for C22H2oN206S 
(440.47) '  C, 59 .99 ;  H ,  4 . 5 8 ;  N ,  6 . 36; S, 7 .28  %, found : C, 60. 1 0; H ,  4 .59 ;  N ,  6.20; S ,  7 .32  %. 
l-(P-D-gluco pyranosyl}-3 -cyano-4 -(thio p hen-2-yl}-6-( 4-chlo rop henyl)-2-p yridino ne (85 d): 
White crystals ; yield 60% (method A); mp 250°C, from methanol; Rf = 0. 3 8  (CH2Ch), IR 
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(KBr em-I) 1 645 (CO) 2240 (CN), 3440 sugar-OH; [ a]25 = 3 3 1 . 2° (c = 8 . 8  mg/mI, methanol); 
I H_ M R  [DMSO-d6 200 M Hz] :  (8, ppm) 3 . 24-3 . 68 (m 6H, H-2" H-3" , H-4" H-5", H-6"a,H-
6"b), 4 59-5 .46 (4 OH exchagab le with D20), 6 .08-6. 1 2  (d, 1 H , H- 1 " , J = 7 .4 Hz) 7 .3 2-7. 37 
(dd, I H , th ienyl H-5 , J = 3 .6  Hz) 7 .59-7 .63 (d, 2H,  J = 8 .6  Hz), 7 .98-8 . 3 1 (m, 3 H), 8 .26-8 3 1  
(d, 2H,  J = 8 .6  Hz); 13 -NM R [DMSO-d6, 200 M Hz] : (8, ppm) 60.6 (C-6") 69.6 (C-5 "), 72 .8  
(C-4") 76.9(C-3 "), 78 .0 (C-2"), 90.7 (C-5), 96. 8 (C- 1 "), 1 1 3 .3 (C-3), 1 1 5 . 2  (CN), 1 28 .6- 1 36 .4 
(aromatic carbons) 1 48 5 (C-6), 1 5 6 . 1 (C-2), 1 63 .5 (C-4). Anal .  Calcd for C22H I9CIN206S 
(4 74 .9 1 ): C, 55 .64 ;  H, 4 .03 ;  N, 5 . 90; S, 6 .75 %, found:  C, 5 5 . 59 ;  H ,  3 .99;  N, 6.0 1 ;  S ,  6 .74 %. 
1-(P-D-glucopyranosyl}-3-cyano-4-[2-(trijluoromethyl)phenyIJ-6-phenyl-2-pyridillone (85e): 
White crystals ; yield 3 2% (method A); mp 1 68°C, from methanol ;  Rf = 0. 87 (CH2Ch) IR 
(KBr, cm-I) 1 650 (CO), 2220 (CN), 3445 sugar-OH; [a]25 = 1 00 .6° (c = 8 mg/ml,  methanol); 
I H-NM R [DMSO-d6, 200 M Hz] : (8, ppm) 3 . 24-3 . 69 (m, 6H, H-2" H-3" ,  H-4", H-5" , H-6"a,H-
6"b), 4 .5 8-5 .45 (4 OH, exchagable with 020), 6. 1 5 -6. 1 8  (d, I H, H - 1 " , J = 7 .4  Hz) 7 .54-7 .57 
(m, 3 H, aromatic), 7 .97-7 .99 (m, 5 H, aromatic), 8 .28 -8 .29  (m, 2 H, aromatic)' 13C-NM R 
[DMSO-d6, 200 M Hz] : (8, ppm) 60.5 (C-6"), 69 .6 (C-5"), 72 .7  (C-4"), 76.9 (C-3"), 78 .0(C-2"), 
92.9 (C-3 ), 96 .7(C- l ") 1 1 4 . 7 (C-5), 1 1 5 .0  (CN) 1 25 .7 - 1 39 . 8  (aromatic carbons) 1 55 .3  (C-6'), 
1 57 .7  (C-2), 1 62 8 (C-4). Anal. Calcd for C25H2!F3N206 (502.44):  C, 59 . 76; H, 4 .2 1 ;  N, 5 . 58  
%,  found :  C ,  59  65 ;  H ,  4 . 30 ;  N ,  5 .5 9  % 
1-(p-D-galactopyranosyl)-3-cyano-4,6-diphenyl-2-pyridinone (88a): White crystals; yield 
43% (method B); mp 2 1 9°C, from methanol;  Rf = 0. 1 6  (CH2Ch), IR (KBr, cm- I) 1 652 (CO) 
224 1 (CN), 3430 sugar-OH; [ a]25 = 6 1  ° (c = 7 . 3 6  mg/ml ,  methanol); I H-NM R [DMSO-d6, 200 
MHz]:  (8, ppm) 3 .24-3 . 67 (m, 6H,  H-2" H-3", HA", H-5",  H-6"a, H-6"b), 4 .59-5 .45 (4 OH, 
exchagable with 020), 6 . 1 3 -6 . 1 7  (d, 1 H, H- 1 " , J = 8 Hz), 7 .5 1 -7 . 59  (m, 6H, aromatic), 7 .73-
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7.77 (m , 2H, aromatic), 7 . 8 8  (s I H, H-5), 8 .22-8 .27 (m, 2H,  aromatic); 1 3C-NMR [DMSO-d6, 
200 MHz]:  (0, ppm) 60 4 (C-6/1), 68 .2 (C-5 /1) 69.9 (C-3 /1 ), 73 . 5  (C-4 /1), 76. 4(C-2/1), 90.5 (C­
l /1) , 97 3 (C-5 ) ,  1 1 3 . 2  (C-3) 1 1 5 . 4  (C ) 1 27 .6- 1 36 .5  (aromatic carbons), 1 48 . 3  (C-6), 1 5 7 .5  
(C-2), 1 63 . 7(C-4). Anal . Ca1cd for C24H22N206 (434 .44): C, 66.3 5 ;  H,  5 . 1 0; N, 6 .45 %, found :  
C, 66.29 ;  H 5 03 · N, 6 .47 %.  
1-(p-D-galactopyrattosyl)-3-cyano-4-(m-tolyl)-6-pltenyl_2-pyridillolle (88b): White crystals;  
yield 5 7% (method B)" mp 1 92°C, from methanol; R[ = 0.2 1 (CH2Cb), 1R (KBr, cm·I) 1 640 
(CO), 2354  (CN), 3 4 3 9  sugar-OH; [af5 = 223 .8°  (c = 8 . 4  mg/ml ,  methanol); IH-NMR 
[DMSO-d6 200 1 Hz) " (0, ppm) 3 . 26-3 .75  (m, 6H, H-2/1 H-3 /1, H-4/1 ,  H-5/1 , H-6/1a,H-6/1b), 2 .4 1 
(s , 3 H, CHJ), 4 .65-5 . 28  (4 OH, exchagable with D20), 6. 1 1 -6. 1 5  (d, 1 H, H- l /l, J = 7 . 8  Hz), 
7 .39-7. 5 7  (m, 7 H, aromatic), 7.86 (s , 1 H, H-5) 8 .26-8 . 28  (m, 2H, aromatic); 13C-NMR 
[OMSO-d6 200 M Hz] :  (0 ppm) 6 1 .0 (C-6/1), 68 .8  (C-5/1), 70.6 (C-3 /1) ,  74 .2  (CA/I), 77 . 1 (C-
2/1), 93 .4  (C- 1 /1), 97 . 8  (C-5), 1 1 5 .4 (C-3 ), 1 1 5 . 7  (CN), 1 26 .4 - 1 39 .0(aromatic carbons), 1 5 7 .5  
(C-6), 1 5 7.9  (C-2), 1 63 .7 (C-4). Anal . Calcd for C25H2-tN206 (44 8 . 47)  C, 66.95 ; H, 5 .39;  N, 
6.25 %,  found. C, 66 8 8 ;  H, 5 .4 1 ; N, 6. 1 9  0/0. 
1 -(p-D-galactopyranosYl}-3-cyano-4-(thiophen-2-yl}-6-phenyl-2-pyridinone (88c): White 
crystals '  yield 47% (method B); mp 1 9 5°C from methanol; Rr = 0.29 (CH2Ch), 1R (KBr, cm·I) 
1 680  (CO), 2234 (CN), 3438  sugar-OH; [a]25 = 1 04 .4° (c = 8 mg/ml ,  methanol); IH NMR 
[DMSO-d6, 200 M Hz] :  (0,  ppm) 3 .25 -3 .68 (m, 6H, H-2/1 H-3 /1 , H-4/ 1 ,  H-5" , H-6/1a,H-6/1b), 
4 59-5 .45  (4 OH, exchagable  with 020), 6. 1 1 -6. 1 4 (d, 1 H, H- l /l ,  J = 7 . 8  Hz), 7 . 3 3 -7 . 37  (m, 1 H, 
thi enyI-H3), 7 . 5 5 -7 . 59  (m, 3 H, aromatic), 7 .97-8 .0 1 (m, 3 H, aromatic), 8 . 23-8 .27 (m, 2H, 
aromatic); 13C-NMR [DMSO-d6, 200 M Hz] :  (0, ppm) 60. 5 (C-6/1), 69 .6  (C-5/1), 72 .8 (C-3"), 
76.9(C-4/1), 7 8 . 0  (C-2/1), 96. 8  (C- 1 "), 90 .4 (C-5), 1 1 3 .2  (C-3), 1 1 5 . 3  (CN), 1 27 .6-
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1 36 .5 (aromati e carbons), l 48 . 3 (C-6), 1 5 7 .4  (C-2), 1 63 . 5  (C-4). Anal .  Calcd for C22H20N206S: 
C, 59 99,  H, 4 . 58 ,  , 6 . 36 ;  S,  7 .28  %; found: C, 60.0 1 ;  H ,  4 .6 1 ;  N, 6 .29;  S, 7 .29 %. 
1-(p-D-galactopyranosyl)-3 -cyallo-4-(thiop ltell-2-yl)-6-( 4 '-c/t[oropltellyl)-2-pyridiflolle (8 8d): 
White elystals ,  yield 77% (method B)' mp 280°C, from meth anol '  Rr= 0.5 1 (CH2Ch), I R  (KBr 
em- 1) 1 645 (CO), 2230 (CN), 3443 sugar-OH; [a]25 = 300° (c = 8 . 4  mg/mJ, methanol); I H 
NM R  [DMSO-d6, 200 M Hz) : (0, ppm) 3 . 49-3 .73 (m, 6H,  H-2" H-3" , HA" H-5", H-6"a,H-
6"b), 4 65-5 . 30  (4 OH exchagable with D20) 6.02-9 .06 (d, 1 H, H- l " , J = 8.2 Hz), 729-7 .34  
(dd I H  J = 4 .0  Hz) 7 . 54-7 .5 9 (d, 2 H, J = 8 . 6  Hz), 7 .9 1 -7 .97 (m,  2H,  thienyl H-2 , 3) ,  7 .99 (s, 
l H, H-5), 8 . 2 1 -8 .25 (d, 2 H, J = 8 . 8  Hz); 1 3C-NMR [DMSO-d6, 200 M Hz):  (0, ppm) 60.4 (C-
6"), 68 .2 (C-5 ") 69 .9  (C-3 "), 73 . 5 (CA" ), 76 .5  (C-2"), 90.7 (C- l "), 97 .4  (C5), 1 1 3 . 3 (C-3 ), 
1 1 5 .4  (CN), 1 28 . 7- 1 36 . 4  (aromatic carbons), 1 48 .5 (C-6), 1 5 6. 1  (C-2), 1 63 . 6  (C-4). Anal . 
Calcd for C22H 19CIN206S:  C, 55 .64 ;  H ,  4 .03 ;  N,  5 .90; S, 6.75 %, found:  C, 55 .63 ;  H, 3 . 98 ;  N, 
5 . 87 ;  S 6 72 %. 
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2 .4 Genera l  Procedure fo r the Synthesi of 4,6-Dianrl- l -(P-FluorobenzoVI)-3-Cyano_2_ 
Pvrid inone (89a-d) 
To a solution of 3 -Deazopyrarnidine (5 mmol) in 50 ml acetonitri le  and 2 ml of pyridine, a 
solution of 1 0  mmol of  p-O uorobenzoyl chloride in aceton iti le  was added gradual ly with 
stirring at room temperature until the reaction was completely j udged by TLC (30 min. ). The 
reaction mixture \\'as evaporated under reduced pressure to yield a sol id. The solid was 
washed \villi water (2 x20ml), and crystal lized in DMSO to give the desired compound (89a­
d) (Scheme 23 ). 
1-(p-Flllorobenzoyl}-4-(tltioplten-2-yl}-6-(p-chlorophenyl)_3-cyano-2-pyridillones (89a): 
White crystals' yield 62%; mp 1 80°C, from DMSO; Rr = 0. 8 5  (6:4 Hexane:ethyl acetate), IR  
(KBr, em-I ) 1 5 8 0  (CO), 1 770 (CO at pyridine N)  2230 (CN); I H-NM R [ DMSO-d6, 200 
M Hz]:  (0, ppm) 7 .36-7. 3 8  (t, 1 H) 7 .46-7.62 (m, 5 H ), 8 . 1 2-8 . 1 3  (d, 1 H, J = 4.0 Hz ), 8 . 1 4-
8 22 (d I H, J = 3 . 8  Hz), 8 . 24-8 .33  (m, 5 H); 13C-NMR [DMSO-d6, 200 M Hz] :  (0 ppm) 95 .4 
(C- l ), 1 04 . 5  (C-5) ,  1 1 6 . 9  (C-3"), 1 1 7 . 4  (CN), 1 25 . 8  (C-2 '), 1 26 . 7  (C-2 , th ienyl), 1 28 . 7  (C-3 ,  
thienyl), 1 28 . 9  (C-3 '), 1 3 l . 2 (C-2"), 1 3 1 .4 (C- l "),  1 3 l .  9 (C-4, thienyl) , 1 3 2 .2  (C- 1 '), 1 3 5 . 7  
(C- 1 ,  thienyl) 1 36 .3  ( C-2) 1 4 8 . 5  (C-4), 1 5 7 .9  (CO at pyridine N), 1 62 . 4  (C-4"), 1 68 . 9  (C-
6); Anal Calcd for CnH J3FN202S (400.43) :  C, 68 .99; H, 3 .27 ;  N, 7 .00;  S,  8 .0 1 %, found : C, 
68 .90; H,  3 .2 5 ;  N, 6.99; S, 7 .90 %. 
1-(p-Fill 0 robe IlZ0 yl}-4-(thio p hen-2-yl)-6-(p-chlo ro p hen yl)-3 -cyano-2-py ridin 0 n es (8 9 b): 
White crystals; yield 65%; mp 1 8 5 °C, from DMSO; Rf = 0 .86  (0 .5 % C H30H in  CH2Cb), IR 
(KBr em - I) 1 592  (CO), 1 754  (CO at  pyridine N) ,  2240 (CN) , I H-NMR [DM SO-d6, 200 
M Hz] : (0, ppm) 7 .33-7. 3 7  (t, 1 H), 7 .46-7 . 59  (m, 4 H ), 8 .0 1 2 -8 .04 (d, 1 H, J = 5 Hz ), 8 . 1 2-
8 . 1 4  (d, l H, J = 3 . 8  Hz), 8 . 2 1 -8 . 33  (m, 5 H); 13C-NMR [DMSO-d6, 200 M Hz] : (0, ppm) 96 .8  
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(C- l ), 1 1 6 5  (C-3 "), 1 1 7 (C-5)  1 1 7 . 4  (CN), 1 23 . 7(C- l " ), 1 28 .9 (C-2") 1 29 . 1 (C-2') 1 29.5 
(C-3 ') 1 3 1 5 (C- I , th ienyl ) 1 32 . 2  (C- l '), 1 3 3 . 3  (C-4') 1 33 . 5  (C-2), 1 3 4 . 3  (C-4 , thienyl ), 
1 3 5 . 7  ( C-2 th ienyl ) 1 36 . 3  (C-3 , thieny!), 1 24 (C- 1 '), 1 29 (C-2'), 1 32 .2  (C-2"), 1 33 . 3  (C-4) , 
1 3 3 5 (C- l ") 1 5 0 2 ( C-3 'II), 1 50 .4  (C- l "'), 1 54 (C-6), 1 5 8  (CO at pyridine N) 1 5 8 . 2  (C-3"), 
1 6 1  (C-4 '), 1 62 (C-4); Anal .Calcd for C23H l2CIFN202S (434 . 87) :  C, 63 . 52 ;  H, 2 .78 ;  N, 6 .44;  
, 7 .3 7%, found.  C 63 . 02 '  H,  2 . 73 ;  N, 6 .45 ;  S, 7 .4 %. 
1 -(p-Fluorobe/lzoyl)-4-(4 �pyridyl)-6-(p-ntethoxyphellyl)-3-cyalto-2-pyridi/lol'l€s (89c): 
White crystals ;  yield 65 %' mp 222°C, from DMSO; Rf = 0 .63 (0.5 % CH30H in CH2Ch), IR 
(KBr em-I ) 1 590 (CO) 1 75 0  (CO at pyridine N), 2233  (CN); lH-NMR [ DM SO-d6, 200 
M Hz]: (8, ppm) 3 . 84 (s, 3 H, OCR3), 7 .07-7. 1 1  (d, 1 H, J = 8 .6  Hz ), 7 . 47-7 .57  (t, 2 H), 7 .8 1 -
7 . 84  (m, 4 H) 8 .22-8 .32  (m, 4 H),  8 . 83 -8 . 86  (d, 2 H ,  J = 5 . 8  Hz; 1 3C_NM R [DMSO-d6, 200 
M Hz) :  (8, ppm) 5 5 . 5  ( OC H3 ), 1 1 4 .5 ( C- 1 ), 1 1 4 . 6  (C-3 '), 1 1 6 . 5  (C-3 " ), 1 1 7 (CN), 1 1 8 (C-3) ,  
1 23 2 ( C-2 "'), 1 24 (C- 1 ') 1 29 (C-2') 1 3 2 .2 (C-2"), 1 33 . 3  (C-4), 1 33 .5 (C- l ") ,  1 50 .2 ( C-3 "'), 
1 50 .4  (C- 1 "'), 1 54 (C-6), 1 5 8 (CO at pyridine N), 1 5 8 .2  (C-3 "), 1 6 1  (C-4'), 1 62 (C-4). 
Anal Calcd for C2J-I13ClFN302 (429 .83) :  C, 67 .06; H, 3 .05 ;  N, 9 .78  %, found: C, 67 .02;  H, 
3 0 1 ,  9.76 %. 
1-(p-Fluorobenzoyl)-4-(3,4-d imethoxyphenYI}-6-(p-methoxyphenyl)-3-cyano-2-
pyridinones (89d) :  White crystals ;  yield 72%; mp 1 97°C, from DMSO; Rf = 0 .8  (6 :4 
hexane / ethyl acetate) IR (KBr, em-I) 1 600 (CO) , 1 768 (CO at pyridine N),  22 1 5  (CN), l H 
NMR [DMSO-d6, 200 M Hz) : (8, ppm) 3 . 82-3 . 8 6  (3s,  9H,  OCR3),  7 .04-7 .09 (d, I H, J = 9.00 
Hz ), 7 1 4-7. 1 8  (d 2 H, J = 8 .60 Hz ),  7 .42 -7 . 5 4  (m, 4 H),  8 .  1 6-8 .32(m,  5 H); 13C-NMR [DMSO­
d6, 200 M Hz] :  (8, ppm) 5 5 .43 -55 .72  ( OCH3) ,  98 .9  (C-5 ) ,  1 1 l . 8 (C- 1 ), 1 1 2 . 3  (C-2, p-3 ,4-
dimetboxyphenyl ) ,  1 1 4 . 4  (C-3 '), 1 1 6.9 (C-5 , p-3,4-dimethoxyphenyl ), 1 1 7 .9  (C-5'), 1 2 1 . 7 
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) ,  1 23 9  ( -6 3 ,4-dimethoxyphenyl 1 27 2 C-2') 1 2 8 2 (C- l ,  3 ,4-dimethoxyphenyl ), 
1 29 5 ( -6'), 1 3 3 2 - 1 "), 1 3 4  (C-2), 1 4 8 . 8  (C-4 3 ,4-dimethoxyphenyl), 1 5 0 2 ( C-3 , 3 ,4-
dimethoxyphenyl), I S O ( - I "), 1 56 0 (  -4'), 1 58 3 C-4), 1 5 9 2 (CO at pyridine N), 1 6 1 8 (C-
4"), 1 62 7  ( -6), Anal alcd for C:l,H2 IF :lOS (4 4 4 8) .  C, 69 .42 ;  H, 4 37 ,  N, 5 .78  %, found 
, 69 20, H,4 36 ,  , 5  0 %). 
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RESULTS AND DISCUSSION 
a,p-Un atur.lted ketones are versati le  reagents that have been extensi\'ely uti lized in 
heterocychc S}1 thesis e\'eraJ new synthetic methods of3-deazapyrimidine deIivati\'es have 
been repol1ed using a,p-unsaturated ketones as star1ing materials (.17,38) It IS of interest to 
tudy the e reactions and to rep0l1 the results o f  our investigations into the potential use 
readI ly obtained 3 -deazapyrarnidines in the field of nuc leoside synthesis and their respective 
biological applications The investigations have resulted in the development of a new 
modi fied ynthetic method of medical ly important nucleoside deIivatives (For more detai ls 
see 4 3 1 
As an initi al target for the assembly of  new nuc leosides, 3 -deazapyramidine 
derivati\'es (82 a-i) are prepared (38) as outlined in scheme 1 7 , The synthesized 3-
deazapyrimidinones were allowed to react with various activated sugar moieties to produce 
the targeted products (83-88). The incorporation o f  any new group wil l  result in change of 
s ize and shape o f  the products. I n  addition i t  may introduce a chiral center, which wil l  result 
in the formation of stereoisomers which may have different pharmacological activities. As a 
result, the introduction of  a new group may increase the biological activity The synthesized 
analogous may ha\'e di fferent activities with respect to changing the size and the shape 
Changing the number of substituents or the degree of unsaturation may result in new 
properties. These types of structural change result in analogues that exhibit either different 
poten cy or di fferent types 0 f activity. 
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NC� /C H2CH3 
o 
CB3 COO-+ NH4 / EtOH / heat � 
Ar' 
o 





_� __ ---=-NH:'="'2 __ �/ 
(82a-i) 
CH3COO-+ � / EtOH / heat 
Compound. 
No. Ar A; 
82a phenyl phenyl 
b 2-tolyl phenyl 
c 3 -tolyl phenyl 
d 2-thienyl phenyl 
e 2-thienyl 4-chlorophenyl 
f 2-tri fluoromethyl phenyl 
phenyl 
g 4-pyridyl 4-methoxyphenyl 
b 4-tolyl 4-chlorophenyl 
i phenyl 4-chlorophenyl 
Scheme 1 7 :  Synthesis on -cyano-4,6-disubstituted pyridine-2(J H)-ones (82a-i) 
CN 
o 
The conesponding nucleoside analogous (83-88) and N-(p-flu oro benzoyl) derivatives 
(89a-d) wre synthesized and their structures are shown in figure 5 .  Compounds (82 a-i) 
contain t:\vo nucleophil ic centers, the oxygen at C-2 and the N-pyridine. The quantum 
mechanics calculations show that the nucleophilicity of the nitrogen atom in the pyridine ring 





(83, 85, 87 and 88) 
Figure 5 General structures o f  3-deazapyrimidinone (82), related nucleosides (83, 85, 87, and  88) and non­
nucleosidt> (89) 
4 5  
Quantum Mechanic  (QM) calculations using densi ty funct ional theory DFT) ere 
u cd to tudy the electron affi nity of  3-deazapyri midine . Gau sian 98 was employed for the 
calculation of g ometri and en rgie . Charge density gas phase calculations wre performed 
at 83 L Y P/6-3 1 G and howed that the charge den i ty on pyridine -atom is 0. 549066 au 
\vh i le the charge den i ty on th ox gen atom at C-2 is 0.408723 au. The HOMO electron 
den it  topolog) on the pyridine nitrogen i higher compared to the HOMO of the carbonyl 
o ygen atom. The data obtained from DFT is con i tent with the data obtained from spectral 
analyse . The results how that the nuc leosides obtained are the N- nucleosides not the 0-
nucleo ide ( Figure 6). 
HOlvfO Electron Den i ty LUMO Electron Denisty 
Figure 6: Molecular Orbital Calculat ions for compound 82e: Wire structures show that the total charge density 
whi le, solid colors (red and blue) show HOMO and LUMO electron density 
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The present PaJt deals with the synthesis of some nove1 3-cyano-4 6-disubsti tuted pyridine-
2(1  H)-ones (82a-i) by the reaction of a,j3-unsaturated ketones with ethylcyanoacetate in the 
presence of ammonium acetate. 3 -cyano-4,6-disubstituted pyridine-2( 1  H)-ones (82a-i) are 
synthesized in a one-pot reaction using substituted acetophenones, aldehydes and ethyl 
cyanoacetate In a catalytic amount o f  ammonium acetate (Method A). While in Method B,  
cyanoacetamide is  used to  synthesize the same products . To examine the two methods, A and 
B m'o paral lel e 'periments have been conducted under the same conditions to synthesize 
compound (82a). It was found that in Method A, the yield was higher than in Method B .  
Method A was selected to synthesize all compounds (82 a-i) no t  only because of the higher 
yield but also to avoid the handling of  the lachrymator chalchones and to save time since no 
prior condensation reaction was needed (Scheme 1 7) .  
I t  has been found that a,j3-unsaturated ketones react with cyanoacetamide through 
conjugate-addition fol lowed by cyc1ization in refluxing ethanol to give the corresponding 3 -




















Ar' N 0 H 
(82a-i) 
Scheme 1 8 :  Suggested mechanism of3 -cyano-4,6-disubstituted pyridine-2(I H)-ones (82 •. i )  
47 
Compounds (82a-i) were obtained and their structures were confirmed on the basis of 
their elemental analysis and spectral data ( IR,  I H-NMR, 1 3 C-NM R) as well as data obtained 
fi-orn modeling calculations. The analytical data for (82e) show that the molecular formula is 
CI6 H9N;!OSCl.  IR 
I H_ 1 R  and 13 C-NMR were used to con firm the structure. The IR 
spect.rum of (82e shO\ved the most signi ficant absorption band for the presence of the 
carbonyl group at 1 600 cm'l . A strong band at 2220 cm,l corresponding to the CN group at 
C-3 and a NH signal appeared at 3430 cm, l . 
The structure of  compound (82e) was confumed using I H-NM R  and 13 C-NMR as 
fol lows : I H-Nrv1R spectrum (8, ppm) [DMSO-d6, 200 M Hz] of  compound (82e) showed a 
strong singlet at 8 = 6 .98 corresponding to the pyridine H-5 . Protons at the 3 ', 4 ', and 5 '­
positions of 2-th iophene showed a sharp splitting pattern. This is true for the protons at the 
3 '  and 5 ' -positions which appear as a pattern of doublet-doublet peaks. The thiophen H-3 ' 
appears as a doublet at 0 = 8 .06 ppm with a coupling constant JID'-H4' = 3 . 8  Hz. H-5 ' appears 
as another doub let at a higher field at 8 = 7 .99 ppm with h':I5'-H4' = 5 .0 Hz. The h igher the 
coupling constant may be attributed to the close contact with more electronegative sulfur 
atom Thus no cross coupl ing has been observed between thiophene H-3 '  and PYlidine H-5 
using NMR techniques. The interaction exist only between protons at the 3 ', 4 '  and 5 ' ­
positions of  the thiophene  ring. These results are supported by Quantum Mechanics 
calculations (QM).  Optimizing the energy showed that the thiophene H-3 '  is present on the 
opposite s ide of the pyridine H-5 with a dihedral angle = - 1 46 .9° (Figure 7) .  The pyridine 
H-5 appears as a sharp singlet at 0 6 .98 ppm due to the distance between H-5 and thiophene 
H-3 '  which is  4 . 595  A. Aromatic protons at 6-position appear as two doublets at 0 7 .5 8 and 
7 . 89  ppm respective ly with equivalent coupling constants (J = 8 .6  Hz). A broad band appears 
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at 1 2 .74 ppm e chang able ith D2 due to th pre ence of NH ( Figure 7). 1 3C-NMR 
[ 0\1 -d6, 200 MHz] ,  gi e the correct and the exact nwnber of carbons with the correct 
chem ical h ift fI r ach carbon. 
Figu re 7:  Optimizing tructure for compound ( 82e) using OFT at B3YLP level using the 6-3 1 G basis set 
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3.2 . 1  Prydinone Glucos ides (83a-e) 
3.2 . 1 . 1  Potass ium Salt Method 
This subsection desclibes the reaction of the potassium salt of  deazapyrimidine 
delivatives (82a-f) with an activated sugar. The potassium salt has been chosen as reactive 
intelmediate to avoid the handl ing of the easy hydrolyzed si lyl compounds and to save time 
since the si lyl method needs longer to be completed. The use of a polar solvent such as H20 
accelerates the reaction rate and saves time. In the 3 -deazapyrimidine potassium salt, there 
are two reactive centers ,  the pyridine ring n itrogen and the carbonyl oxygen at C-2. A sole 
N-nucleoside product has been isolated in high yield without any contaminate formation of 
the O-nucleoside. An additional approach in trying to understand the reactivity difference 
between N and 0 is by using the DFT method implemented into the Gaussian program at the 
BL3YP level with the 6-3 1 G* basis set It is clear that the experimental results are fully 
consistent with data obtai ned from the higher level of  theory as the BL3YP level with the 6-
3 1  G* basis set. These results showed h igher electron density on the pyridine ring nitrogen 
over exocycl ic oxygen atom at C-2 . The NM R  data for H-J /I appear at the higher field 
corresponding to the N-nucleosides and not the O-nucleosides . For the sake of  simplicity of 
presentation, the synthesis and the structure determination of the nucleosides (83a-e) wil l  be 
discussed in detail .  a-acetobromoglucose (7) is reacted with the appropriate 3 -
deazapyrimidine derivatives (82a-f) in the presence of aqueous potassium hydroxide 
presumably through a \Valden inversion, to yield the corresponding glucosides (83a-e) 
(Scheme 1 9) .  Since Walden inversion occurs in  the halogen repl acement reaction, the halide 
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with the a-con figuration yields the ,B-isomer. The remaining 3 -deazapyrim idine galactosides 
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Scheme 1 9 : Two ways synthesis of the prydinone gluGosides (83a-e) 
3.2 . 1 .2 The SHyl Method 
� 
S 
This subsection describes the reaction of the silyl detivative (84) with an activated 
sugar to give the corresponding N-nucleosides (83d). A l ikely mechan ism for the formation 
of the n ucleoside (83d) involves an intermediate cyclic carbonium ion, as shown in Scheme 
20  The  reaction o f  a nucleophil ic base should take place from the  less s terically hindered ,B-
5 1  
face of the cation to give the ,B-nucleoside, as observed. The reaction is earned out under dry 
nitrogen and without isolation of  the si lyl intermediate. The use o f  polar solvents such as 
acetonitli le accelerates the reaction rate. When a stoichiomelic amount of the catalyst 
(TM OTQ is used, the reacti on proceeds smoothly to give typical I H-NM R spectra of 
compound (83 d)  with the same chemical shift of the anomeric proton H-J " that is obtained 
by K-sal t procedure and the same melting point. The synthesis and the structure 






o OA< e 
. 0  + Snct.OAc 




� AcO AoO Ac 
o 
(&Jd) 
Scheme 20: Schematic Mechanism of the S il yl Method 
s 
CN 
The structure of  the obtained nucleoside is determined as fol lows: F irst, compound 
(83d) is optical ly active and is characterized by a spec ific rotation [a]25 = 1 7 .9° (c = 9 .2  
mg/ml ,  chloroform). The IR spectrum of (83d) showed the presence of acetoxy carbonyl 
groups at 1 75 2  cm- I . A strong band appeared at 1 64 1  cm-! corresponding to the pyridine 
carbonyl at C-2 . The structure of the compound (83d) was further confirmed by IH-NMR 
and COSY. The COSY spectrum was used to assign intra-proton interactions (Figures 8- 1 0). 
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lear interaction between H-5 of the pyridine ring and ortho-protons at 6-position is shown 
A cross peak interact ion o f  aromatic region is obselved. In addition, the cross-peak 
interaction between anomeric proton H-J " and H-2 " is also obselVed. No cross-peak 
interact ion between th iophene H-3 / and PYI1dine H-5 was obtained which is consistent with 
data obtained from quantum mechanics calculation. 
Since I H_ M R  spectroscopy is powerful tool, it was used routinely for the 
determination of the relati e con figurations (a, fJ ). The l H-NM R (CDCb) showed the � 
con figuration of  nuc leoside (83d). The anomel1c proton H- 1 "  appears as doublet at relatively 
low field (8 = 6 25-6 .3 0). The spin-spin coupl ing constant JHl"-H2" = 8 .20 Hz indicates that 
the protons H- 1 "  and H-2"  are in diaxial orientation. The H-2" and H-3 "  signal appear as 
multiplet at 8 = 5 . 3 9-5 . 45 .  The H-5" signal appears as multiplet at 8 = 4.00.  The  H2-6" 
signal appears as multiplet at 8 = 4 . 1 9-4 .25 . Protons of the four acetoxy groups appear as 
four s inglet around 8 = 1 . 93 -2 .07 .  Similar results are obtained for other nucleosides (83a-e) 
All coupl ing constants are g iven in the experimental section. 
Compound (83d) was further confumed using 13C-NMR spectroscopy. These results 
are in agreement with the assigned structure. The 13C-NM R (CDCb) spectrum of (83d) was 
characterized by a signal at 8 = 95 .0  ppm corresponding to the C- l "  atom of  the � 
configuration. T he s ignals appear at 8 = 1 48 . 7 ,  1 63 . 1  ppm assigned for C-6 and C-4 , 
respectively. S ignals at 8 = 1 68 .9 ,  1 70 .2 ,  1 70 .3 and 1 70 .4 ppm assign for the acetoxy 
carbonyl carbon. Signals corresponding to pyridine C-5 and C-3 resonate at 8 = 9 1 . 9 and 
1 1 3 .9 ppm, respectively. Another five signals at 8 = 7 1 . 7 , 70. 9, 67 . 8 , 67 . 1 and 6 1 . 7 ppm 
assign for the sugar carbons as C-2", C-3" ,  C-4",  C-5'1 and C-6" respective ly. On the other 
53  
hand, the carbonyl carbon o f pyridine appears at 8 = 1 63 . 1  ppm and the nitri le  carbon appears 
at 8 = 1 1 4 5 ppm. 
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3.2 .2  Am monolYsi  o f N u c leos ides C83a-e) 
Ammonolysis of the nucleosides (83a-e) using saturated ammonia in methanol  gives free 
nuc1eosides (85 a-e) in 42-75% yield (Scheme 2 1 ). 
r' 















2-to lyl phenyl 
2 -thienyl phenyl 
2 -thienyl 4-ch lorophenyJ 
2-trifluoromethyl phenyl 
phenyl 
Scheme 2 1 :  Ammonolysis step of the Pryliinone g lucosides 
Ar 
C '  
o 
The stnlctures o f  the obtained nuc1eosides (85 a-e) are elucidated by studying their 
IR, lHNMR and l3C NMR spectra which are in accordance with the s tructures proposed from 
the result o f  the elemental analysis as well as the data obtained from the modeling 
calculation. The NOESY (two dimensional nuclear overhouser spectroscopy) is used to 
assign the inter-protons interaction. 
The IR (KBr) absorption spectra of compounds (85a-e) showed a characteristic band 
at 344 1 cm-1 due to the sugar hydroxy groups. Another band at 2924 cm-1 can be assigned to 
the n itrile group. A strong absorption band at 1 63 7  cm-1 is attributed to the stretching 
vibration o f  the carbonyl group at C-2 . In addition to these bands, the ether l inkage of the 
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gJ ucopyranoside ring system shows a broad band at 1 05 0  cm-l It is c lear that, the stretching 
nbration band of the four acetoxy carbonyl groups within the 1 700- 1 75 0  cm- l range have 
disappeared 
The lH-NM R (D r O-d6) spectrum of compound (8Se) is con firmed by the 
appearance ofa  doublet at 8 = 6 1 7  ppm corresponding to the anomer1c proton of  the glucose 
moiety \yith a spin-spin coupl ing constant equal to 7 . 40 Hz corresponding to the diaxial 
orientation of  the B- 1 /I and H-2/1 protons indicating the formation of  only one f:l-isomer. The 
13C-NMR (DM O-d6) spectrum of (8Se) is characterized by a s ignal at 8 = 96.7 ppm 
corresponding to the C- l /1 atom o f  glucose residue. No more signals appear in the region 8 = 
1 .  9-2 0 ppm corresponding to the methyl of  acetoxy groups. See experimental part for more 
details. 
The phase sensitive NOESY spectrum of (8Sa) was col lected at 25°C in CDCb 
(Figure 1 2). All inter ring NOESY cross peak between the anomeric proton at C- l "  and the 
arrha-phenyl protons at C-6 are also seen. This conclusion obtained from the NOESY study 
was fully supported by quantum mechanics calculations using the Gaussian 98 program. 
The conformation analysis gave the most stable conformer, whereby the p lane of  the pyridine 
ring b isects the sugar moiety whi le  the aromatic subistiuent at position-6 appears twisted 
relative to the pyridine plane (Figure 1 1 ) . The calculated average distance between B- 1 '  and 
the artha-aromatic protons is 2 .7 1 and 3 . 7 1 AO respectively. These  calculated distances 
bet\,."een B- 1 and the artha-aromatic protons are fully consistent with the observed NOESY 
results. 
5 9  
Figure 1 1 : Optimizing tructure for compounds (85a,e) using DFT at B3YLP level using the 6-3 I G basis set 
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3.2.3 Pvrid inone Galacto ides 
The s tructures of compounds (87a-e) were establ ished unambiguously on the basis of 
elemental analysis and spectral data. All these compounds are ,P-anomers. The 
stereochemistry can be explained in terms of the SN2 substitution reaction between the 0.-
bromosugar and the nucleophi l ic  P)'lldinone anion. Al l products are optical ly active and 
were charactelized by speci fic rotation (Scheme 22).  
AT n° r' 0 R 
(82 a-e) 
90A< OA< ° 
.,. KOB ' "do", + �O • OAe Br 
(86) 
Com pound. 




d 2 -thienyl 
e 2-trifl uoromethyl 
phenyl 









Sch eme 22 :  Synthesis o f Pyridinone Galactoside (87a-e) in aqueous KOH 
The IR (KBr) spectra of compounds (87a-e) are cbaractellzed by the presence of the 
carbonyl group in the 1 75 0- 1 780  cm-t region and the presence o f a  s trong band at 1 64 1  cm-! 
corresponding to the carbonyl group at pyridine C-2. In addition to these bands the 
galactopyranoside ling shows strong bands at 1 064 and 1 1 05 cm-l corresponding to ether 
l inkage. 
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As has already been discussed , I H_ R spectroscopy is routinely used to determine 
the relati\'e con figuration (l- or fi-) of nucleosides . In the ,B-configuration, the anomeric 
proton H- 1 "  at 8 = 6 3 1  ppm is in a diaxial relationship with H-2" o f  the hexapyranosyl ring 
system \\ Ith a coupling constant greater than 7.5 Hz which indicates that the configuration of 
the hexapyranose is fi 
Analysis of  the IH_ f R  spectrum of (87 a )  reveals the presence of a doublet at 8 
6. 27-6 3 1  ppm and J = 8 00 Hz which can be attributed to the anomeric proton H- J "  l inked to 
pyridme n itrogen ignals for H-2" and H-3 " are observed as multiplets at 8 = 5 .5 1 -5 . 74 
ppm and and the s ignal cOITesponding to H-4"  as a multip let at 5 .2 1 -5 .28  ppm in CDCh 
respectively This indicates that the protons are axial ly oriented and that they exist in 4C 1 CD) 
conformation and the ,B-configuration. Then H-6' and H-6" s ignals were observed as a 
mul tiplet at 4 1 7 -4 .28  ppm The 1 2  protons of the four acetoxy groups appear at 8 = 1 . 8 8 ,  
2 04, 2 0 5  and 2 22  ppm within the range expected for the equatorial acetoxy groups. The 
pyridinone protons appear in the region 8 = 7 .26-8 09 ppm whereas the H-5 appears as a 
strong smglet at 8 = 7 .66 ppm. Signals observed at 8 = 7 . 5 0-7 .70 ppm and 8 04-8 .09 ppm 
correspond to the aromatic protons. 
The structures of compounds (87a-e) are also con firmed by !3C-NM R spectra 
( ee experimental part for more details) The 13C-NMR spectrum o[ compound (87a), as an 
example, is characterized by a signal at 8 = 94 .9 ppm corresponding to the C- 1 "  atom of the 
,B-anomer The four s ignals which appear at 8 = 1 68 9 l 70 .2 ,  1 70 .3  and 1 70.4 ppm (four 
acetoxy carbonyl carbon) are due to the four acetoxy carbonyl carbon atoms of the sugar 
moiety The four s ignals which are shown at 8 = 20. 5 ,  20 .6 ,  20 .6 and 20 .7 ppm are 
attributed to the methyl carbons of the same groups. The five signals at 8 = 7 1  8 , 67 .9 ,  70.9,  
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67 .2  and 6 1 .  ppm assigned to /3-anomer of C-2" ,  C-3 " ,  C-4" , C-5"and C-6' respectively 
The pyridinone IJ -NM R signals seen at 8 = 1 57 , 1 1 4 0, 1 62 4 , 94 ° and 1 57 2 ppm 
con'espond to -2,  C-3 , -4 C-5 and C-6 respectively. A strong signal appears at 8 = 1 1 5 4 
ppm corresponding to the cyano group at C-3 . The 13 -NM R signals o f  the aryl groups at the 
positions 4 and 6 o f pyridinone nucleus appear within the range 1 27 3 - 1 36 . 8 ppm 
1 -(f3-D-galactop;Tanosyl)-3 -deazapyrimidine den atives (88a-d) were obtained by the 
ammonoly is of (87 a-d) u ing triethylamine in  methanol at room temperature for 48 hours 
The reaction mixture was puri fied using column chromatography to give the COlTect 
microanalytical results in yield 5 7-770/0 (Scheme 23)  
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The structures o f  the obtained galatosides were confirmed by elemental analysis,  IR 
spectra and NM R  data The IR. (KBr) spectra of the free galac tosides (88a-d) were 
characterized by the absence 0 f the ester carbonyl at 1 75 0  cm·l . The presence 0 f the broad 
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band within 3 200-3700 cm- ' is due to the [our hydroxyl groups of  the galactose moiety while 
the strong band appears at 1 63 9  cm-' corresponding to the carbonyl group at .-2 
The structure o[ compound (88a) was confirmed by ' H-NM R  and CO Y The COSY 
pe t!Um wa used to assign intra-protons interactions Figures 1 3  and 1 4  show a cross peak 
mteraction \\ ithin the aromatic region between H-5 oCthe pyridine ling and artha-protons at 
the 6-positlOn same as in the acetylated product 87a) The cross-peak interaction between 
the anomelic proton H-J " and H-� " is also observed. No cross-peak interaction between the 
hydroxyl protons at C-2 ", C-3 ", C-4 ", C-6 " and any other protons in the system was 
ob ef\'ed 
The ' H- f R  (DM O-d6) spectra of the nucleosides (88a-d) are characterized by the 
appearance of a doublet at (5 = 6. 02-6.06 ppm, at a relatively lower field than other sugar 
ring protons This corresponds to the anomeric proton of  the galactose moiety and the large 
coupling constant, J = 8 .20  Hz, c an be attributed to the diaxial orientation oCthe H- l "  and H-
21/ protons which indicates the p-configuration and the 4C \  (D) conformation The 13C-NM R 
D f O-d(.) spectrum of  (88a )  is characterized by a signal at (5 = 97 .4  ppm corresponding to 
the C- l "  atom of the glucose residue. No other signals were observed at (5 ;:::: 20 ppm region 
corresponding to the methyl of the acetoxy groups. 
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Figure 14: COSY spectnun of compound (88d) 
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This part deals \"'ith the synthesis of 1 -(p-tluorobenzoyl)-3 -cyano-4 ,6-diaryl-2-pyridinone 
(89a-d) by the reaction of 3 -deazapyramidine derivatives (82a-i) with 4 -fluorobenzoyl 
ch loride in dlY acetonitri l e. The reaction afTorded a sole product within 30 min. 1 -(p-
tl uorobenzoyl )-3 -cyano-4 ,6-diaryl-2-pyridinones (89a-d) were obtained in a 62-72% yield 
( cherne 24) .  The s tructures of compounds (89a-d) were con firmed by elemental analysis 
and spectral data (IR, l H-NMR, 13  C-NM R). The analytical data for (89a) reveals a molecular 
formula, C:!6H l�4N202. The IR spectrum of  (89a) shows the presence of  n;vo carbonyl 
groups at ] 5 8 0  cm-1 and at 1 7 70 cm-1 corresponding to the carbonyl group at C-2 and another 

















3 ,4 -Dimethoxyphenyl 
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Scheme 24:  Synthesis of 1 -(p-fluorobenzoyl)-3 -cyano-4,6-diaryl-2-pyrid inone (89a-d) 
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Summary 
This study includes the design and synthesis of some new 3 -deazapyrimidines and their 
nucleoside analogues .  Moreover, the  reactions with the Guoro derivatives produced new 
fluOIinated pyridine analogues The structures or all final products were establ ished and 
con finned by di fferent spectroscopic tools. Quantum mechanical calculations supported the 
suggested structmes of the obtained nuc leosides. The biological act ivity o r the products is 
incorporated in this study. All  om work is summarized in the fol lowing points :  
A. ynthesis of 3-Deazapyrim idine Derivatives 
3 -Deazopyr-amidine delivatives (82a-i) were prepared as outlined in (Scheme 1 7). 
They were synthesized by the reaction of a,p-unsaturated ketones and ethylcyanoacetate in 
the presence of ammonium acetate. The reaction was accompl ished via the conjugate 
addition of  enolate anion to the a,p-unsaturated ketones fol lowed by cycl ization in refluxing 
ethanol to give the cOlTesponding 3 -cyano-4,6-distributed pyridine-2(I H)-ones (82a-i) in 
good yield. 
B. Nucleosides Derived from 3-Deazapvrim idines 
Pyridione nucleosides (83a-e) and (87a-e) were synthesized by the reaction between 
the activated deazopyrimidine derivatives (82 a-e) either through the formation of the K-salt 
or the s i lyl  intennediate. The activated intennediate was al lowed to react in situ with 
activated sugar molecules to produce the target nucleosides (83 a-e) and (87a-e) (Schemes 1 9  
and 22) .  
69 
RemovIng the acetyl groups from the sugar moiety was camed out using either 
saturated ammonia in methanol or triethylamine to give free n ucleosides (8Sa-e) or (88a-e) in 
high Yleld ( hemes 2 1  and 23)  
Quantum Mechanics (Q f )  calculations were used to  support the data obtained from 
the spectral analy is QM was also used to detect the more reactive center among the 
pyridinone moiety M odeling was also used to enhance the 3 D-view of these molecules and 
to e amine the obtained conformers 
D 
Thi part deals with the synthesis of new 4 6-diaryl- l -( 4' - fluorobenzoyl)-3 -cyano-
2 1 H)-pyridinone (89a-d). The reaction of pyridine base (82a-i) with p-fluorobenzoyl 
chJonde afforded the corresponding pyridinone (89a-d) (Scheme 25 ). 
E. Bio logica l Application 
The synthesized compounds are c lass ified into two main groups according to their 
biological activity. The most prominent analogue was (89a) which resulted in a decrease in 
the viability of the cells .  Therefore (89a) could be considered as a potential anticancer agent 
in which both concentrations were effective ( I OO and 200 I-lM). However analogue (8Sc) was 
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Scheme 2 5 :  General synthetic scheme for all nucleosides and non-nucleosides derivatives 
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4. Biologica l  ct ivity 
4. 1 I n troduction 
Cancer IS  a class  of  d iseases or disorders characterized by uncontrol led division of 
cel ls  and the abi l ity of  the e cells to invade other tissues either by direct growth into adjacent 
tis ue through In vasion or by implantation into distant sites by metastasis This unregulated 
growth i caused by damage to D A, resulting in mutations to genes that encode for proteins 
control ling e l l  dJ\ l sion ( 1 )  
Deyelopment of  drug therapy progressed rapidly after the discovery of D A as the 
primary geneti material in 1 944 and subsequent elucidation of the physical structure in 
1 95 3(2) ince the nucleic acids D A and RNA are the initial precursors in the fOImation of  
protein that are responsible for many biological and physiological processes, i t  i s  logical that 
these molecules could be viell ed as potential targets for drug design and development (3) 
D A and RNA are biopolymers composed of  nuc1eosides held together by phosphodiester 
l inkages and as a resu l t  the nucleosides can also be considered as potential targets (2,3) 
[t ,vas not until the 1 960's ,  that chemistlY involving n uc1eosides and nuc1eotides 
provided the fundamenta l  in frastructure and synthetic methodology necessary to produce 
numerous biologically active naturally occurring and structural ly modified nuc1eos ides . The 
biological activity of  anticancer agents such as 5 -fluoro-2 '-deoxyuridine (FUDR), 
arabinosy1cytidine (ara-C), 8 -azainosine along with the discovery of a potent antiviral 
n ucleoside, arabinosyladenosine (ara-A), and antitumor agent, toyocamycin revealed the 
potential value o f  modified nucleoside Analogues as chemotherapeutic agents (Figure 1 5 ).(4,5) 
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Figu re 1 5 :  Some FDA-approved nucleoside drugs 
The importance of  these nucleoside analogues was later confirmed with the 
emergence o f  HIV as the m ain etiological agent of AIDS.(6) The first dlUg approved for the 
treatment of HIV was the modified nucleoside AZT which inhibits HIV - 1  reverse 
transcriptase (7) Furthermore, several other nucleoside analogues involved in inhibition of  
HN - 1  reverse transcriptase namely ddC, ddI, d4  T and 3 TC,  have provided even more 
sign ificance to the use of  nuc leoside analogues as b iological ly potent chemotherapeutic 
agents (Figure 1 6) .(7-9) 
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DespIte these examples, c l imcal use of  these drugs is limited due to several factors, includmg 
toxicity, the \\ Ide range of side effects , problems with l ipophil icity and crossing cel l 
membranes, and susceptibi l i ty to enzymatic cleavage (9) This has prompted researchers to 
sear h for more ad\ anced chemotherapeutic agents that could address these issues 
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Vida rabin. 
( A ra - ) 
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Figu re 1 6  Some potent nucleoside-based inhibitors of HIV- 1  RT 
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ytotoxic nucleoside analogues NA) were among the first chemotherapeutic agents to 
be mtroduced for the medical treatment of  cancer (10) This fami ly of compounds has grown to 
mclude a \ aliety of  purine and pyrimidine nucleoside derivatives with activity in both solid 
tumors and hematological malign ancies ( I I) These agents behave as antimetabolites and 
compete with natural nucleosides The eITectiveness of these agents results from their abil ity 
to cause co\'alent modi fication of D A Thus they get incorporated into the genetic matelial 
during D rep lication and destroy it by preventing the fidel ity of the repair system within 
the 0 'A ( I�) 
Recent progress in the identification and characterization ofnucleoside mechanisms of  
anticancer nucleoside activity provides opportuni ties for possible  antitumor effects . ( IO) 
Since they are hydrophi l ic compounds they require special transporter proteins to enter the 
cells Once inside the cells they are activated to become triphosphate derivatives which can 
be incorporated within D A or RNA and damage them by interfering within the enzymes 
responsible for their synthesis such as polymerases . This results in damaging the genetic 
component o f  the cel l  and eventually leading to apoptosis ( 10·12) 
4. 1 . 1 . 1  Purine a nd Pyrim id ine  ucleoside Analogues 
ucleoside analogues (NA) constitute a pharmacological ly diverse fami ly, 
comprising cytotoxic compoun ds ,  antiviral agents and immunosuppressive molecules .  The 
anticancer n ucleosides include several analogues of physiologic pyrimidine and purine 
nucleosides. The t\vo primary purine analogues are 2-chlorodeoxyadenosine (2-CdA, 
cladribine) and 2 -fluoro-ara-A-monophosphate (fludarabine).( IO, I I) These drugs have mostly 
been used in the treatment o f  l ow-grade hematological malign ancies .  Among the cunently 
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available pyrimidine nucleobases and analogues cytosine arabinoside (ara-C, cytarabine) is 
extensively used in the treatment of acute leukemia. 
DiO uorodeoxycytidine (gemcitabine) has demonstrated activity in a valiety of solid 
tumours and ce11ain hemato logical malignancies, whi le  5 -o. uorourac il and capecitabine have 
demonstrated activity in colorectal and breast cancers (Figure 1 7). 
01-1 OH 
CytaTabine Gemcitabine 2-CDA,Cladeibine Fl udarab i De 
capecltabine 5-0uorouracil 
Figure 1 7 '  PyTImi.dine and purine analogues used in chemotherapy. Gemcitabine, (ara-C, cytarabine) are 
pyrimidine analogues, whereas fludarabine and (2-CdA, cladribine) are purine analogues. 5 -fluorouracil and 
and capecitabme are examples for lluoropyrimidine 
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4. 1 . 1 .2 Pyrim idine uc leo ide Analogues and  Nucleobases 
4. 1 . 1 .2 . 1  Bio logical  Properties of  Pyrimidine Nucleoside 
Pyrimidine nucleosides have become the focus of  recent research since many of these 
nucleosides have been foun d to exhibit sign i ficant biological activity. PYIimidine 
ribon ucleosides and pyrimidine-2 ' -deoxyribonucleosides which contain an electron 
withdrawing group at position 3 and/or 5 have been shown to exh ibit significant antiviral 
properties. For example 4 -amino-3 - iluoro- I -(8-D-ribofuranosyl )-pytidine-2 ( 1 H)-one (90) 
has been shown to inhibit the growth of  the L 1 2 1 0  Lymphoid Leukemia cell with IC50 = 1 .  07 
* 1 0.5 while the 2 '-deoxy derivative of  (90) was shown to have less activity against 
Lymphoid Leukemia L 1 2 1 0  cells ([7) FurtheITIlore, the same study showed that the triacetyl 
derivative exhibited similar but l ess potent activity to that of (90) 
OR 
(90) 
I -Deazaguanine has shown activity against the growth of  mouse mammary 
carcinoma (1 8) Certain  1 - and 3 -deazapurines have shown antibacterial ,  anticancer and 
antiviral activityY9) Important biological activity of deaza analogues of guanine is 
anticipated from the metabol ism in microbial and mammalian system. 3-Deazaguanosine has 
shown potent broad spectrum activity against various DNA and RNA vimses(20) while, 3 -
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deazauridine has been sho\\.'TI to exhibit signi ficant antiviral propelt ies .  It has been shown to 
inhibit the growth ofmi croorganisms and L 1 2 1 0  leukemiayl) 
4. 1 . 1 .2 .2 B io logical Propertie of Deazapyrimidine 
Various p)'1imidines have been shown to have important biological prope1ties in 
medicinal and agricultural studies. (D) For example, selective inhibitors of human 
immunodeficiency virus type 1 reverse transcriptase (HN - IR T) was found to be affected by 
some deazap)'1midine derivatives with ICso of  1 9  nm. (1 4) Compounds 3 -[(4,7 -dimethyl 
benzoxazol-2-yl)J- arnino-5 -ethyl-6-methyl pyridine-2( 1 H)-one and the corresponding 4 ,7-
d ich loro analogue (9 1 )  have inhibited the spread of  HN-I infection by 95% in MT4 cel l 
cultme and were selected for c lin ical trails as antiviral agents. 4 -benzyl pyridinone (92 ) 
possess potent HN - 1  speci fic  reverse transcriptase inhibitory properties. ( 15) 
(9 1 )  X = NH, CH2 
R[ >  Rz = 4,7-dimethyl 
= 4,7-dichloro 
92) X = S, R1 = H,  R2 = R3 = CH3 
X = CH2>R1 = C H3, R2 = Et, R3 = NH2 





(93) R = CH3, R' = H 
= CH2CH3, R' = H 
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4. 1 . 1 .2 .3 Fluoro pyrimidine 
5 -Fluorouraci l  (5 -FU) and 5- iluoro-2'-deoxyuridine (FUDR) have antitumor activity 
in patients \\ ith colorectal, pancreatic, breast and head and neck cancers (22) These agents 
require an acti,'e intennediate such as 5 - iluorodeoxyuridine 5 ' -monophosphate (5 -FdUM P),  
5 -fluorouridine tnphosphate (5 -FUTP) or 5 -fluorodeoxyuridine triphosphate (5 -FdUTP) The 
cytotoxic effects of these compounds include (i) inhibition of the target enzyme thymidylate 
synthase  (T ) by 5 -FdUM P  resulting in depletion ofthymidine n ucleotides and inhibition of 
D synthesis and repair: ( i i )  incorporation into RNA resulting in  abnormal RNA 
processing and function, and (ii i) misincorporation of 5 -FdUT P and deoxyuridine 
uiphosphate dUTP) into D , producing damage to nascent  DNA. 
4.1 .2 Nucleosides and Cancer 
The growing importance of  nucleosides as cytotoxic agents has stemmed both from 
the de,relopment o fnewer compounds with broad appl icabil i ty to common cancers, and from 
an understanding of  their mechanisms of action, enab ling pharmacological intervention to 
potentiate the antitumor effects of  these compounds.(22) 
ucleosides analogues and their corresponding nucleobases and as a result, have been 
investigated due to their inherent structural resemblance to the naturally occurring nucleosides 
and nucleobases as the fundamental building b locks of many b io logical systems Synthetic 
nucleoside analogues can be used in chemotherapy to treat cancer due to the intertwined 
relationship between physiologic and synthetic nucleosides (22) 
Cytotoxic nucleoside analogues are antimetabolites which interfere with nucleic acid 
synthesis These agents are general ly S-phase specific, and c an exert cytotoxic activity either 
by being incorporated and altering the DNA and RNA macromolecules structures. It can 
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disrupt the normal repl ication process by interfeling with the normal Watson-Crick base 
pailing, thereby preferential ly kil l  rapidly dividing cells such as tumor cel ls  Synthetic 
nucleo I de analogues can also interfere with various enzymes involved in nucleic acid 
s}llthes l uch as polymerases (e.g 0 A polymerase), phosphorylases (e.g Thymidine 
Phosphorylase) and kinases (e.g nucleoside kinase). However, some fami ly of analogues 
causes cytotoxic actinty by modifYing the metabolism of  physiologic nucleosides. (22, 23) 
ucleoside analogues exert their anti cancer potential if they destroy the cancerous cells by 
the process o f  programmed cell death or the disruption of cel l cycle progression. (23) 
4. 1 .2 . 1 Apopto i 
ince the mid-nineteenth centwy, many observations have indicated that cell death 
plays a considerable role during physiological processes of multicel lular organisms, 
particularly during embryogenesis and metamorphosis. (24, 25) The term programmed cell 
death was introduced in 1 964, proposing that cell  death during development is not of an 
accidentiaI nature but fol lows a sequence o f  contro lled steps leading to locally and 
temporal ly defined self-des truction.(26) Eventually, the term apoptosis had been coined in 
order to describe the morphological processes leading to control led cellular self-destruction 
and was first introduced in a publication by Kerr, Wyll ie and Currie in 1 972 .(27) 
Apoptosis or programmed cell death is a physiological process that is activated to 
eliminate unwanted, damaged, aged, or misplaced cells during embryonic development and 
tissue homeostasis Apoptotic cells can be recognized by stereotypical morphological 
changes the cel l  shrinks, shows deformation and loses contact to i ts neighbouring cells Its 
chromatin condenses and marginates at the nuclear membrane, the p lasma membrane is 
blebbing or budding, and finally the cell is fragmented into compact membrane-enclosed 
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structures, cal led 'apoptotic bodies' \ hich contain cytosol the condensed chromatin, and 
organel le (Figure I ) The apoptotic bodies are engul fed by macrophages and thus are 
remo\ ed fi'om the tis ue \\ ithout causing an inllammatOlY response (28) 
Apopto is is in contrast to the necrotic mode of cell-death in which case the cells 
suffer a major msult ,  resultmg in a loss of  membrane integrity, swel l ing and disrupture of the 
cel ls Dunng ne rosis ,  the cel lular contents are released uncontro l led into the cel l 's 
environment \\,]l Ich re ults in damage to the sun'ounding cel ls and a strong inll ammatory 
response in the cOlTesponding tissue. (29) 
NECROSIS APOPTOSIS 
Figu re 1 8 '  Hallmarks of the apoptotic and necrotic cell death process. Apoptosis includes cellularshrinking, 
chromatin condensation and margination at the nuclear periphery with the eventual formation of membrane­
bound apoptotic bodies that contain organelles, cytosol and nuclear fragments and are phagocytosed without 
triggering inflammatory processes The necrotic cell swells, becomes leaky and finally is disrupted and releases 
its contents into the surrounding tissue resulting in inflammation 
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lany natural and synthetic D -targeting agents are now under study. Many of 
these are qUite promising in cancer therapy (i . e , in the treatment of  acute promyelocytic 
leukemia , where new chemotherapeutic agents with di iTerent mechanisms of action are 
te ted D A topoisomerase enzymes are important nuclear enzymes They regulate DNA 
metabolism and aiTect replication transcription, chromatin assembly, and consequently also 
cell divi ion The functions of the D A topoisomerases I, I l a, and I I f3  thus have s ignificant 
consequences [or cancer development and cancer chemotherapyYo. 3 1) I ndeed, impOitant 
chemotherapeutic agents that are either in cl inical use or the subjects of clinical trials target 
these enzymes These include etoposide and doxorubicin (topo isomerase n inhibitors) and 
topotecan and irinotecan (topo isomerase I inhibitors). Inhib itors of topoisomerase n either 
stabi l ize D A-topo isomerase IT complexes by blocking DNA rel igation and thereby cause 
direct D A damage (e.g. ,  etopos ide) or block their catalytic activity e.g , dexrazoxane) 
without causing D A damage.(3 1 ) 
It has been knmvn for some time that D A-damaging topoisomerase II inhibitory 
anticancer drugs, such as etoposide and doxorubicin cause apoptosis . Etoposide 
(VP 1 6) l ike other drugs, is used in the treatment o[ various tumors, such as breast and lung 
cancer and leukemia (32) However, the mechan isms for the induction of apoptosis are less 
wel l understood It has been shown that apoptosis induced by the chemotherapeutic drug 
etoposide is caspase-dependent  (family o f  protines known as cystein-dependent aspartate­
directed proteases) Two classes o f  caspase-dependent pathways have been ident ified. The 
first is dependent on the release of mitochondrial factors , which initiate the apoptosis 
process In this case, apoptosis can be inhibited by overexpression ofBc1-2 . The second class 
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is not dependent on mitochondrial factors and overexpression o f  Bcl-2 fails to pre\'ent 
apoptos) ( 3) 
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4.2 l a terial  and  
4.2 . ] Reagent 
uc1eoside analogues were synthesized and purified, and then dissolved in di -methyl 
ul foxide (0  1 0, igma Aldrich hemie GmbH teinheim, Germany) to prepare 1 00 and 
200 fl 1 so lution and stored at -20°e. 
4.2.2 Ti  ue Culture 
Human promyelocytic leukemia HL-60 cell l ine (ATCC, USA) was grown in OM EM 
medIum (GIB O-B RL) supplemented with 20% fetal cal f serum (GIBCO-BRL), 1 00 
units ml penic i l l in-streptomycin (GIBCO-BRL). The cells were maintained at 37°C in a 5 %  
C02 incubator After reaching con fiuency, the cells were subcultured into 96-wells culture 
plates, al lowed to grow for 1 day and treated with various concentrations ofnucleosides and 
nucleobases 
4.2.3 l\ITT Cell Pro liferation Assay 
Cells 'were plated in  96-well p lates at a density 4 x l  03 cells/weI ll ! 00 flL of the 
appropriate culture medium and treated with the compounds at concentrations of 1 00-200 
rrliv1 for 24 hrs.  In parallel  the cells were treated with 0. 1 % of  OMSO as a control .  A MTT 
[3 -(4 ,5-dimetbylthiazol-2-yl)-2,5 -diphenyltetrazolium bromide] assay (Alexis, USA) was 
performed later according to the manufacturer instructions to examine the cytotoxic effect of 
these n uc1eosides After adding the MTT reagent the plate was further incubated for 1 -4 hrs, 
followed by measuring the absorbance. This assay is based on the cel lular cleavage of the 
tetrazolium salt, MTT, i nto formazan that is  soluble in cel l culture medium and is  measured 
at 450  nm directly in 9 6-well assay p lates. The amount of the fonnazan dye (absorbance) 
generated by the activity o f  dehydrogenases in cells by the intact mitochondria is directly 
8 7  
proportional to the number of  l iving cells in culture All nucleoside compounds tested were 
dissoh ed in 0 1 0 and subsequently diluted in the culture medium to obtain the final 
concentratIons that are going to be tested ( 1 00-200 11M) before treatment of  the cultured 
cel l 
4.3 Re u lts a nd Oi cu ion 
4.3. 1 E ffects 0 11 H L-60 Proliferation and I ntegrity by N ucleoside 
From the i TT cel l  prol iferat ion assay we can categorize the effects of the tested 
analogue into three groups as fol lows (Figures 1 9-22): 
Group 1 Protective effect (% viabi l i ty 90% and above). 
2 Group 2 0 effect (% viabi l i ty 70-89 %). 
3 Group 3 Min imal to moderate effect (% viabi l ity 69% and below). 
According to this class ification the majority of the nucleosides were grouped into group 
1 or 2 Compound (89a) was found to be the most prominent analogues which resulted 
in a decrease in the viab i li ty of the celis, and hence can be consider d as a potential anti 
cancer agents in which both concentrations are effective ( 1 00 and 200 11M) .  In contrast 
the rest o f the analoguous d isplayed only slight anti -tumor activity. However (8Sc) was 
found to be effectiye at a concenteration of  200 11M only. This suggests that al l these 
analogues are capable of protecting against apoptosis or have no effect at al l .  This 
finding also suggests that acetylated sugar i ncreases the b ioavail abi l i ty (their del ivery 
into the cel l )  o f  the nucleoside and therefore its effectiveness. The in it ial observations 
about the apoptotic potential of these drugs in  the HL-60 cell line prompted us to further 
imoestigate the mechanism of their apoptotic induction. The controls that were used in 
8 8  
the e expeJ;ments i f  not speci fied were untreated cel ls as negative control and sodium 
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Figure 1 9 : % Viability in HL-60 cell line treated with 3 -deazapyrimidine derivative (82a-i) from MTT cell proliferation assay 
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Figu re 2 1 :  % Viability in HL-60 cell line treated with pyridinone galactosides (87a-d) from MTT cell proliferation assay 
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Figure 22 :  % Viability in HL-60 celJ line treated non-nucleoside derivatives (89a-d) from MTT cell proliferation assay 
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For a compound to act as an anti-cancer agent, i t  must be able to induce 
apoptoslS  As such, in this study the abil i ty orsynthetic nuc1eosides analogues to induce 
cell death \\ as examined From the MTT cell proli feration assay We showed that two 
of  the t\\ enty seven compounds studied in this project, which were 89a) and (8Se), had 
the most PO\\ erful antiprol iferative effect They result in a decrease in the percentage or 
cell viabil i ty reaching 30% and 50% respectively Interestingly, the rest were less 
effective, probably because of the d ifference in the structure, which affects the solubil ity 
and hence renders their uptake by the cells efficiently. M oreover, some of  the 
nucleosides resulted in an decrease in  the percentage of  viabi l i ty such as (8Se) and 
(88a) which suggest that they may exert an anti-apoptotic potential, and therefore they 
might act as anti-neurodegenerative agents, since the key feature o f  these diseases is the 
excess in cell death. 
Biological activity results estab lished an interesting Structure-Activity Relationship 
SAR) SAR of nuc1eosides (83a-e, 8Sa-e 87a-e and 88a-d) and non-nucleosides (89a-d) 
showed interesting resu lts. Different derivatives of 3 -deazapyrimidine have shown different 
activities according to the n ature of the substituents at either the 4 - or 6-position or the 
pyridine ring. The resu lts have shown that 2-thiophene at the 4 -position has the highest 
acti'lty among al l analogues. In addition,  the aryl groups at the 6-position have shO\vn 
similar activities .  For example 4 -(th iophen-2-yl)-6-phenyl-3 -cyano-2( 1 H)-pyridinones (82 d) 
and 4-(thiophen-2-yl)-6-(p-chlorophenyl)-3 -cyano-2 ( 1 H)-pyridinones (82 e) have shown 
similar act ivities at lower and h igher concentrations. This result indicates that aryl groups at 
the 6-position have no sign i ficant effects based on the results obtained from the biological 
screening. M eanwhile, nucleosides containing the glucopyranosyl ring system showed 
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higher activity than the galactose isomer For example glucosides (83a-e) have shov.'T1 better 
acti\'ities compared to the corresponding galactoside analogues (87a-e) ot all free 
nucleosldes ( 3a-e) showed higber activity due to the solubi l i ty factor, other derivatives with 
10\\ olublity showed better activity such as (89a) 
l ean\\ bile, more interesting results were obtained from the non-nucleoside 
analogues (89a-d) AR has explained these results as fol lows: 
Tbe solubil ity factor might not be the main factor because a low soluble non­
nucleoside (89a is continued to have the highest potential activity. 
4.4 Conclu  ion 
ucleoside analogues are either pwine analogues or pyrimidine analogues designed 
to inhibit D RNA synthesis . In either case, the structures of the drugs c losely resemble 
their natural counterparts. They are of special importance because they exhibit a \vide range 
of biological properties , including anti-tumor potential . In order for a drug to be considered 
an anti-cancer agent it has to be able to destroy the cancerous cells and spare most normal 
cel ls ideal ly through the mechanism of apoptosis. The synthetic nucleosides investigated 
(exclusively (89a) and (8Se» in this study result in a decrease in cel l  viabi lity and therefore 
m ight be considered as possible candidates to act as anti-tumor compounds. This inhibition 
occurs at 1 00 and 200 /lM concentration and was detected after 24 hrs. In addition, the rest of 
the tested analogue showed no effect or preservation of the cells integrity, and as a result 
might be considered as an anti-neurodegenerative agent. These data indicate that compounds 
(89a) and (8Se) could be considered as an effective anti-cancer. Wh eras , the sugar could 
control the activity; the substituents at the 4-position and fluorinated benzoyl at pyridine-N 
have the most promising biological activity. 
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4.5 Reco m mendation a n d  Future \-Vork 
In the field ofnucleosides and their derivatives there has been increased focus on the design, 
synthes Is and study of structure activity relationships (SAR) Data obtained from our \ ork 
has shown that the activity has a direct relation to the substituents attached to the pyridinone 
ring at di fferent positions. The procedure used to obtain these targeted products encourages 
us to gi,'e more attention [or the synthesis of more derivatives to eval uate both of the 
biologl al a tiv-ity and the undesired side effects. Interestingly, most of our studied products 
have shown high bioavi labi l i ty and passive membrane d i ffusion. In fact, some of  these novel 
synthesized nucleosides have high cytotoxic propelties to most tumor cell l ines via the 
enhanced apoptosis Due to the results obtained from the structural activity relationships , the 
n ucleoside and non-nucleoside analogues have increased our attention to further study more 
modified products to evaluate the biological properties. 
The fol lowing wil l  be emphasized in our future work: 
Synthes izing new derivatives with d ifferent pyridine substituents based on ribose and 
deoxyribose nuc leosides. 
Studying QSAR, which may be ultimately be used to develop a new drug that has 
higher activity. 
Testing these agents on different cell l ines. 
Tracking the toxic effect and elucidate the sequence of events involved ill the 
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Figure 23 : Infrared spectra for (82a), (83a) and (85a) 
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Figu re 32:  lH-N MR spectrum o f  compound (82d) 
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Figure3 3 :  lJCNMR spectrum of compound (82d) 
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Figure 34: lHNMR spectrum of compound (82e) 
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Figure 38 : lHNMR spectrum of compowld (82g) 
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Figu re 4 1 :  13CNMR spectrum of compound (82h) 
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Figu re 45: Be NMR spectrum of compound (83a) 
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Figure 46 : lI lNMR spectrum of compound (83b) 
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Figu re 48:  IHNMR spectrum o f  compound (83 c) 
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Figure 50 : 'HNMR spectrum of compound (83d) 
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Figure 55: 13CNMR spectrum of compound (85a) 
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Figu re 57:  J)CNMR. spectrum of compound (85b) 
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Figure 58 : IHNMR spectrum of compound (85e) 
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Figure 60 : IHNMR spectrum of compound (85d) 
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Figu re 6 1 :  13CNMR 5pectrum of compound (85d) 
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Figure 62:  1�1R spectrum of compound (8Se) 
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Figu re 63: \3CNMR spectrum of compound (8Se) 
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A'�; 
AcO OAc 0 
(87a) 
-
� . -= � �  
h _  • 
- 'C) 
:: � ; ;,.0 :. : � : �  , � . . �  ... " c-';: ;.:  
'1
1 =0 'i i � 
-':i
11 1:: I i I I I t l � 
140 I Z Q 1 1 O  50 60 4 0  
Figu re 66: DC NMR spectrum of compound (87a) 
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Figu re 7 1 : IHNMR spectrum of compound (87d) 
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Figure 72 : 13CNMR spectrum of compound (87d) 
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Figu re 73:  lHNMR spectrum of compound (87c) 
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Figure 74:  Be NMR spectrum of compound (87e) 
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Figu re 75: IHNMR spectrum of compound (88a) 
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Figu re 77 : lHNMR spectrum o fcompound (88b)  
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Figure 78 : 13CNMR. spectrum of compound (88b) 
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Figure 80 : 1[ INMR spectrum of compound (88e) 
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Figure 83:  lHNMR spectrum of compound (88d) in D20 
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Figu re 86 : I3C NMR spectrum of compound (89a) 
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Fi�ure 7: IHNMR spectrum of compound (89b) 
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Figure 88 :  l3e NMR spectrum of compound (89b) 
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Figure 90 : ])C NMR spectrum of compound (89c) 
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Figure 9 1 :  IHNMR spectrum of compound (89d) 
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Figure 92: DC NMR spectrum of compound (89d) 
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